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A B S T R A C T
Background
Treatment of cancer is increasingly effective but associated with short and long term side effects. Oral side effects, including oral
mucositis (mouth ulceration), remain a major source of illness despite the use of a variety of agents to treat them.
Objectives
To assess the effectiveness of interventions for treating oralmucositis or its associated pain in patients with cancer receiving chemotherapy
or radiotherapy or both.
Search methods
Electronic searches of Cochrane Oral Health Group and PaPaS Trials Registers (to 1 June 2010), CENTRAL via The Cochrane Library
(to Issue 2, 2010), MEDLINE via OVID (1950 to 1 June 2010), EMBASE via OVID (1980 to 1 June 2010), CINAHL via EBSCO
(1980 to 1 June 2010), CANCERLIT via PubMed (1950 to 1 June 2010), OpenSIGLE (1980 to 1 June 2010) and LILACS via the
Virtual Health Library (1980 to 1 June 2010) were undertaken. Reference lists from relevant articles were searched and the authors of
eligible trials were contacted to identify trials and obtain additional information.
Selection criteria
All randomised controlled trials comparing agents prescribed to treat oral mucositis in people receiving chemotherapy or radiotherapy
or both. Outcomes were oral mucositis, time to heal mucositis, oral pain, duration of pain control, dysphagia, systemic infection,
amount of analgesia, length of hospitalisation, cost and quality of life.
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Data collection and analysis
Data were independently extracted, in duplicate, by two review authors. Authors were contacted for details of randomisation, blindness
and withdrawals. Risk of bias assessment was carried out on six domains. The Cochrane Collaboration statistical guidelines were
followed and risk ratio (RR) values calculated using fixed-effect models (less than 3 trials in each meta-analysis).
Main results
Thirty-two trials involving 1505 patients satisfied the inclusion criteria. Three comparisons for mucositis treatment including two or
more trials were: benzydamine HCl versus placebo, sucralfate versus placebo and low level laser versus sham procedure. Only the low
level laser showed a reduction in severe mucositis when compared with the sham procedure, RR 5.28 (95% confidence interval (CI)
2.30 to 12.13).
Only 3 comparisons included more than one trial for pain control: patient controlled analgesia (PCA) compared to the continuous
infusion method, therapist versus control, cognitive behaviour therapy versus control. There was no evidence of a difference in mean
pain score between PCA and continuous infusion, however, less opiate was used per hour for PCA, mean difference 0.65 mg/hour
(95% CI 0.09 to 1.20), and the duration of pain was less 1.9 days (95% CI 0.3 to 3.5).
Authors’ conclusions
There is limited evidence from two small trials that low level laser treatment reduces the severity of the mucositis. Less opiate is used
for PCA versus continuous infusion. Further, well designed, placebo or no treatment controlled trials assessing the effectiveness of
interventions investigated in this review and new interventions for treating mucositis are needed.
P L A I N L A N G U A G E S U M M A R Y
Interventions for treating oral mucositis for patients with cancer receiving treatment
Using a low level laser may reduce the severity of ulcers caused by cancer treatment.
Treatments for cancer can cause severe ulcers (sores) in the mouth. These can be painful and slow to heal. The review found some
evidence that using a laser relieves or cures the ulcers. Morphine can control the pain. Although using morphine automatically on a
constant drip, or self controlled use, provide similar relief, people use less morphine when they are controlling it themselves.
B A C K G R O U N D
Treatment of malignant diseases with cytotoxic chemotherapy or
radiotherapy or both, is becoming increasinglymore effective but it
is associated with short and long term side effects. Among the clin-
ically important acute side effects is disruption in the function and
integrity of the oral mucosa. The consequences of this include se-
vere ulceration (oral mucositis) and fungal infection of the mouth
(oral candidiasis). These disease and treatment induced complica-
tions may also produce oral discomfort and pain, poor nutrition,
delays in administration of chemotherapy or radiotherapy, reduc-
tions in the doses of chemotherapy drugs, increased length of in-
patient stays and associated economic costs and in some patients
life threatening infection (septicaemia in neutropenic patients).
Oral complications remain a major source of illness despite the
use of a variety of agents to prevent them. There are variations in
usage between cancer centres in terms of the mouthcare regimen
used. Compliance with recommended use of product is variable
and there are conflicting reports of the effectiveness of prophylac-
tic agents. The qualitative and quantitative benefits, side effects
and costs of oral therapies are of importance to the cancer teams
responsible for the treatment of patients.
There have been several traditional reviews published and most
of these present a general discussion for both chemotherapy and
radiotherapy induced oral side effects (De Pauw 1997; Denning
1992; Knox 2000; Lortholary 1997; Plevova 1999; Shaw 2000;
Stevens 1995; Symonds 1998; Verdi 1993;White 1993). The con-
clusions drawn and recommendations made vary from advocating
a particular therapy to recommending oral care procedures that
have not been systematically investigated. Five systematic reviews,
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which were not Cochrane reviews, have focused on the preven-
tion and treatment of oral mucositis in patients with cancer. One
older review published in 1998 concluded that for most strategies
reviewed there is insufficient evidence to draw any conclusions re-
garding their effectiveness (Kowanko 1998). The other three more
recent reviews focused on patients with head and neck cancer only
(Shih 2002; Sutherland 2001; Trotti 2003), and two were unable
to draw definite conclusions regarding the effectiveness of any of
the agents tested, however in the Sutherland 2001 review themain
analysis combined all the interventions in one meta-analysis and
found a beneficial effect of prophylactic interventions. This pool-
ing of interventions is impossible to interpret and therefore not
helpful.
A systematic review looking at antimicrobial therapy to prevent or
treatmucositis identified 31prospective trials (not just randomised
trials) of which 13 reported some benefit. The review concludes
that there is no clear pattern emerging regarding the benefit or
otherwise of antimicrobial use to manage mucositis, and there is
limited evidence supporting the use of antimicrobial agents for
reducing oral mucositis (Donnelly 2003).
Another review looked at granulocyte macrophage-colony stimu-
lating factor (GM-CSF) for the prevention and treatment of oral
mucositis (Fung 2002). This review included studies of different
types including some with historical controls. The authors con-
clude that although there are published studies, these studies are
limited and the use of systemic or topical GM-CSF cannot be
recommended for prevention or treatment of mucositis.
This review is part of a series of four Cochrane reviews looking
at the prevention and treatment of oral mucositis and oral can-
didiasis in patients with cancer receiving treatment (Worthington
2007a; Clarkson 2007; Worthington 2007b). The review for the
prevention of oral mucositis (Worthington 2007b) found 11 out
of the 33 interventions investigated showed some evidence of a
benefit (albeit sometimes weak) for either preventing or reducing
the severity of mucositis. Interventions with more than one trial
were amifostine, Chinese medicine, hydrolytic enzymes and ice
chips (cryotherapy). Interventions with only one study were: ben-
zydamine, calcium phosphate, etoposide bolus, honey, iseganan,
oral care and zinc sulphate. This review is currently being updated
and will be published in 2010.
O B J E C T I V E S
To assess the effectiveness of interventions (which may include
placebo or no treatment) for the treatment of oral mucositis or its
associated pain for patients with cancer receiving chemotherapy or
radiotherapy or both. The following null hypotheses were tested,
against alternative hypotheses of a difference, for comparisons be-
tween groups treated for mucositis.
• There is no difference in the proportion of patients with
improvement in mucositis after treatment for mucositis.
• There is no difference in the proportion of patients with
mucositis eradicated after treatment for mucositis.
• There is no difference in the proportion of patients with
severe mucositis (≥grade 3) after treatment for mucositis
• There is no difference in the mean number of days taken to
heal.
• There is no difference in the mean pain scores after
treatment or analgesia for mucositis.
The review is divided into two parts, one concerning interventions
for the treatment of mucositis and one concerning the control of
the pain in patients with mucositis.
In this review we also addressed the hypothesis of no difference
between groups treated for mucositis for the following outcomes
if data were available from studies which included a primary out-
come:
• relief of dysphagia (problems during eating);
• incidence of systemic infection;
• amount of analgesia;
• days stay in hospital;
• cost of oral care;
• patient quality of life.
The following subgroup analyses were proposed a priori:
• cancer type (head and neck, other solid tumours,
leukaemia, and mixed);
• cancer treatment type;
• age group (children, adults, children and adults).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials (RCTs) were eligible for inclu-
sion in this review.
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Types of participants
Anyone with cancer who is receiving chemotherapy or radiother-
apy or both and has oral mucositis.
Types of interventions
Active agents: any intervention for the treatment of oral mucositis
or its associated pain.
Control: may be placebo, no treatment, or another active inter-
vention.
Types of outcome measures
The following outcomes were considered in this review:
• Mucositis at different levels of severity
• Days to heal (mean)
• Oral pain scores or categories
• Relief of dysphagia
• Incidence of systemic infection
• Amount of analgesia
• Days stay in hospital
• Cost of oral care
• Patient quality of life.
Search methods for identification of studies
This review is part of a series of four reviews on the prevention
and treatment of oral candidiasis and oral mucositis in patients
with cancer, and the same search strategies were used for all four
reviews.
The searches attempted to identify all relevant trials irrespective
of language. Papers not in English were translated by members
of The Cochrane Collaboration. Sensitive search strategies were
developed for each database using a combination of free text
and MeSH terms. The MEDLINE and CANCERLIT searches
combined the subject search with the Cochrane Highly Sensitive
Search Strategy (CHSSS) for identifying randomized trials in MED-
LINE: sensitivity maximising version (2009 revision) as referenced
in Chapter 6.4.11.1 and detailed in boxes 6.4a and 6.4.c of The
Cochrane Handbook for Systematic Reviews of Interventions Version
5.0.2 [updated September 2009] (Higgins 2009). The EMBASE
and CINAHL searches were combined with sensitive search strate-
gies developed by the Cochrane Oral Health Group for identi-
fying RCTs. The LILACs subject search was combined with the
Brazilian Cochrane Centre search strategy for identifying RCTs in
LILACS.
Electronic searching - the databases searched were:
Cochrane Oral Health Group Trials Register (to 1 June 2010) (see
Appendix 1)
Cochrane Pain, Palliative and Supportive Care (PaPaS) Group Tri-
als Register (to 1 June 2010) (see Appendix 1)
Cochrane Central Register of Controlled Trials (CENTRAL) (via
The Cochrane Library 2010, Issue 2, 1 June 2010) (see Appendix
2)
MEDLINE and MEDLINE Pre-indexed via OVID (1950 to 1
June 2010) (see Appendix 3)
EMBASE via OVID (1980 to 1 June 2010) (see Appendix 4)
CINAHL via EBSCO (1980 to 1 June 2010) (see Appendix 5)
CANCERLIT via PubMed (1950 to 1 June 2010) (see Appendix
6)
OpenSIGLE (1980 to 1 June 2010) (see Appendix 7)
LILACS via The Virtual Health Library (see Appendix 8).
Only handsearching carried out by The Cochrane Collaboration
was included in the search (see master list www.cochrane.org).
The controlled trials database (www.controlled-trials.com) was
also searched to identify ongoing and completed trials and to con-
tact trialists for further information about these trials.
The reference list of related review articles and all articles obtained
were checked for further trials. Authors of trial reports and spe-
cialists in the field known to the review authors were written to
concerning further published and unpublished trials.
The review will be updated every 2 years using the Cochrane
OralHealth Group Trials Register, CENTRAL,MEDLINE, EM-
BASE, CINAHL, CANCERLIT and LILACS. The search of
OpenSIGLE was discontinued as this database ceased being up-
dated in 2005.
Data collection and analysis
Selection of studies
The titles and abstracts (when available) of all reports identified
through the searches were scanned by two review authors. Full
reports were obtained for trials appearing to meet the inclusion
criteria or for which there was insufficient information in the title
and abstract to make a clear decision. The full reports obtained
from all the electronic and other methods of searching were as-
sessed independently, in duplicate, by two review authors to es-
tablish whether the trials met the inclusion criteria or not. Dis-
agreements were resolved by discussion.
Data extraction and management
Data were extracted by two review authors independently us-
ing specially designed data extraction forms. The characteristics
of the trial participants, interventions and outcomes for the in-
cluded trials are presented in the study tables. Mucositis may be
dichotomised at different levels of severity. In order to maximise
the availability of similar outcome data, we recorded the number
of patients in each category of mucositis usually on a 0 to 4 scale,
and used the following dichotomies: 0 versus 1+, 0-1 versus 2+, 0-
2 versus 3+. Pain was assessed on visual analogue scales (0 to 100),
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the means and standard deviations for each group were recorded.
The duration of trials and timing of assessments were recorded in
order to make a decision about which to include for commonal-
ity. We also recorded the country where the trial was conducted
and whether a dentist was involved in the investigation. Authors
of full study reports and abstracts identified were contacted for
clarification or for further information.
Assessment of risk of bias in included studies
This was conducted using the recommended approach for assess-
ing risk of bias in studies included in Cochrane reviews (Higgins
2009). It is a two-part tool, addressing the six specific domains
(namely sequence generation, allocation concealment, blinding,
incomplete outcome data, selective outcome reporting and ‘other
issues’). Each domain includes one or more specific entries in a
‘Risk of bias’ table. Within each entry, the first part of the tool
involves describing what was reported to have happened in the
study. The second part of the tool involves assigning a judgement
relating to the risk of bias for that entry. This is achieved by an-
swering a pre-specified question about the adequacy of the study
in relation to the entry, such that a judgement of ‘Yes’ indicates low
risk of bias, ‘No’ indicates high risk of bias, and ‘Unclear’ indicates
unclear or unknown risk of bias.
The domains of sequence generation, allocation concealment, in-
complete outcome data and selective outcome reporting are each
addressed in the tool by a single entry for each study. For blinding
two entries were used because assessments need to be made sepa-
rately for a) patients and carers and b) outcome assessor. The final
domain (‘other sources of bias’) was assessed as a single entry for
studies as a whole.
The risk of bias assessment was undertaken independently and
in duplicate by two review authors as part of the data extraction
process.
Summarising risk of bias for a study:
After taking into account the additional information provided by
the authors of the trials, studies were grouped into the following
categories. We assumed that the risk of bias was the same for all
outcomes and each study was assessed as follows:
Risk of bias Interpretation Within a study Across studies
Low risk of bias. Plausible bias unlikely to seriously
alter the results.
Low risk of bias for all key domains. Most information is from studies at
low risk of bias.
Unclear risk of bias. Plausible bias that raises some
doubt about the results.
Unclear risk of bias for one or more
key domains.
Most information is from studies at
low or unclear risk of bias
High risk of bias. Plausible bias that seriously weak-
ens confidence in the results
High risk of bias for one or more
key domains.
The proportion of information
from studies at high risk of bias is
sufficient to affect the interpreta-
tion of results
A risk of bias table was completed for each included study (Risk
of bias in included studies). Results are presented graphically by
study (see Figure 1) and by domain over all studies (Figure 2) .
5Interventions for treating oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
6Interventions for treating oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Measure of treatment effect
For dichotomous outcomes, the estimates of effect of an interven-
tion were expressed as risk ratios together with 95% confidence in-
tervals. For continuous outcomes mean differences together with
95% confidence intervals were used.
Dealing with missing data
Intention-to-treat analyses were conducted if possible. Methods
outlined the handbook (Higgins 2009) were used to impute miss-
ing standard deviations if these could not be obtained from au-
thors.
Assessment of heterogeneity
The significance of any discrepancies in the estimates of the treat-
ment effects from the different trials was assessed by means of
Cochran’s test for heterogeneity and quantified by I2 statistics.
Heterogeneity was considered statistically significant if P value was
< 0.1. A rough guide to the interpretation of I2 given in the Hand-
book is: 0 to 40% might not be important, 30 to 60% may repre-
sent moderate heterogeneity, 50 to 90%may represent substantial
heterogeneity, 75 to 100% considerable heterogeneity (Higgins
2009).
Assessment of reporting biases
We tabulated all the outcomes considered here.
Data synthesis
Meta-analyses were done only with studies of similar comparisons.
Risk ratios were combined for dichotomous data using random-
effects models (fixed-effect models used if less than 3 studies in
meta-analysis).
It was planned to undertake a sensitivity analysis to examine the
effect of concealed allocation and blind outcome assessment on the
overall estimates of effect. However there were insufficient trials
to undertake this.
Subgroup analysis and investigation of heterogeneity
We proposed a priori to conduct subgroup analyses for different
cancer types (head and neck, other solid tumours, haematological
and mixed), cancer treatment (chemotherapy, radiotherapy) and
age groups (children, adults and mixed).
We planned to investigate clinical heterogeneity by examining the
different cancer types and age groups.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
See Characteristics of included studies table.
See Characteristics of excluded studies table.
Electronic searches identified over 6000 titles and abstracts and
from this we obtained over 600 full reports. Ninety-five studies
were considered eligible according to the defined criteria for trial
design, participants, interventions and outcomes.
Characteristics of the trial setting and investigators
Of the 95 eligible studies, 64 were subsequently excluded for the
following reasons:
• not randomised controlled trial (RCT) (12 studies);
• abstract only (27 studies: where possible authors were
contacted for further information but no replies were received);
• unsuitable design (14 studies: reasons include: trial stopped
when obtained result (unplanned), all patients allocated but only
given intervention if they had mucositis, cross-over but unsure if
mucositis at second period);
• protocol violation (1 study: recruitment was halted early
due to ethical concerns relating to rinse);
• no useable data (6 studies: progression of mucositis,
number of ulcers, area covered, means);
• no relevant outcomes (3 studies);
• unclear information on number of withdrawals (1 study).
Of the 32 included trials, 13 were conducted in USA (Coda 1997;
Dodd 2000; Dodd 2003; Hill 1990; Hill 1991; Hill 1992; Kim
1985; Loprinzi 1997; Mackie 1991; Schubert 1987; Syrjala 1992;
Syrjala 1995; Wadleigh 1992), two in Germany (Schedler 1994;
Zucker 1998), two in Italy (Chiara 2001; Porta 1994), two in
the UK (Barber 2007; Pillitteri 1998), two in Turkey (Cubukcu
2007; Papila 2003), and one each in Pakistan (Malik 1997), Den-
mark (Ehrnrooth 2001), Austria (Hejna 2001), India (Kaushal
2001), Iran (Baharvand 2010), Czech Republic (Kostrica 2002),
Sweden (Masucci 2005), Egypt (El-Housseiny 2007), Belgium
(Genot-Klastersky 2008), Brazil (Kuhn2009) andSpain (Valcarcel
2000). Six of the trials were multicentre studies (Baharvand 2010;
Barber 2007;Dodd 2003; Loprinzi 1997;Masucci 2005; Schubert
1987). Twenty of the trials received external funding, 10 obtained
government funding, nine acknowledged assistance from the phar-
maceutical industry (Dodd 2003; Hill 1990; Hill 1991; Kim
1985; Mackie 1991; Malik 1997; Masucci 2005; Schubert 1987;
Valcarcel 2000). The providers and assessors of the treatments
were mainly medical staff although seven of the trials involved a
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dentist (Cubukcu 2007; Dodd 2000; Dodd 2003; Kuhn 2009;
Masucci 2005; Schubert 1987; Wadleigh 1992), four a hygienist
(Coda 1997; Hill 1990; Hill 1991; Hill 1992) and in two trials
only patients were involved in the mucositis assessment (Dodd
2000; Loprinzi 1997).
Characteristics of the participants
Twenty-eight of the 32 included trials recruited only adult pa-
tients with cancer, four included only children (Cubukcu 2007;
El-Housseiny 2007; Kuhn 2009; Mackie 1991). Fourteen trials
included patients treated for a combination of leukaemia and solid
tumours, eight trials included patients with head and neck can-
cer (Barber 2007; Dodd 2003; Ehrnrooth 2001; Kaushal 2001;
Kim 1985; Kostrica 2002; Masucci 2005; Schedler 1994), a fur-
ther six trials only treated patients with solid cancers (Chiara
2001; Cubukcu 2007; Dodd 2000; Hejna 2001; Papila 2003;
Porta 1994) and two trials included patients with leukaemia only
(Genot-Klastersky 2008; Valcarcel 2000). The cancer type was
unclear in two trials (Baharvand 2010; El-Housseiny 2007). The
patients in 11 trials received bone marrow transplants and stem
cell transplants (Coda 1997; Genot-Klastersky 2008; Hill 1990;
Hill 1991; Hill 1992; Mackie 1991; Pillitteri 1998; Syrjala 1992;
Syrjala 1995; Valcarcel 2000; Zucker 1998). The patients in
22 trials received chemotherapy only (Baharvand 2010; Chiara
2001; Coda 1997; Cubukcu 2007; Dodd 2000; El-Housseiny
2007; Hejna 2001; Hill 1990; Hill 1991; Hill 1992; Kuhn 2009;
Loprinzi 1997; Mackie 1991; Malik 1997; Papila 2003; Pillitteri
1998; Porta 1994; Syrjala 1992; Syrjala 1995; Valcarcel 2000;
Wadleigh 1992; Zucker 1998), in eight trials the patient received
only radiotherapy (Barber 2007; Dodd 2003; Ehrnrooth 2001;
Kaushal 2001; Kim 1985; Kostrica 2002;Masucci 2005; Schedler
1994) and in two trials the patient received both chemotherapy
and radiotherapy (Genot-Klastersky 2008; Schubert 1987).
Although the reporting of the reasons for withdrawal by study
group was unclear in nine trials, the percentage of withdrawals was
clear in all trials apart from two and this ranged from 0% to 60%
with a median of 9%.
Characteristics of the interventions
Treatment of mucositis
Twenty-one trials looked at the effectiveness of 15 agents treating
clinical signs of mucositis. Ten of these were placebo controlled
trials and a further 11 trials had other comparisons as shownbelow:
• allopurinol versus placebo (Porta 1994);
• benzydamine HCl versus placebo (Kim 1985; Schubert
1987);
• chlorhexidine versus salt and soda (Dodd 2000);
• debridement versus no debridement (Cubukcu 2007);
• Gelcaire versus sucralfate and mucaine (Barber 2007);
• GM-CSF (granulocyte macrophage-colony stimulating
factor) versus no treatment (Masucci 2005);
• GM-CSF versus placebo (Valcarcel 2000);
• GM-CSF versus povidone iodine (Hejna 2001);
• GM-CSF versus antimycotic mouthrinse (Papila 2003);
• human placental extract versus Disprin™ (Kaushal 2001);
• laser versus sham treatment (Genot-Klastersky 2008;Kuhn
2009);
• ’magic’ (lidocaine solution, diphenhydramine
hydrochloride and aluminium hydroxide suspension) versus salt
and soda (Dodd 2000);
• phenytoin mouthrinse versus placebo (Baharvand 2010);
• polyvariant intramuscular immunoglobulin versus placebo
(Schedler 1994);
• sucralfate versus placebo (Chiara 2001; Loprinzi 1997);
• sucralfate versus salt and soda (Dodd 2003);
• tetrachlorodecaoxide versus placebo (Malik 1997);
• vitamin E versus placebo (Wadleigh 1992);
• vitamin E (topical) versus vitamin E (swallowed)
(El-Housseiny 2007).
Control of mucositis pain
Fourteen trials examined the effectiveness of pain control in pa-
tients with mucositis (Baharvand 2010; Coda 1997; Dodd 2000;
Dodd 2003; Ehrnrooth 2001; Hill 1990; Hill 1991; Hill 1992;
Kostrica 2002; Mackie 1991; Pillitteri 1998; Syrjala 1992; Syrjala
1995; Zucker 1998). Fourteen different agents were assessed, tri-
als frequently looking at different methods of delivery of the same
agent. Seven trials included a group receiving morphine and four
trials compared patient controlled versus continuous infusion of
pain control. All the comparisons are shown below:
• alfentanil versus morphine (Hill 1992);
• hydromorphone versus morphine (Coda 1997);
• sufentanil versus morphine (Coda 1997);
• morphine versus tricyclic antidepressant (Ehrnrooth 2001);
• sufentanil versus hydromorphone (Coda 1997);
• patient controlled analgesia (PCA) versus continuous
infusion delivery of morphine (Hill 1990; Mackie 1991; Pillitteri
1998);
• pharmacokinetically based patient controlled analgesic
infusion system (PKPCA) versus PCA for delivery of morphine
(Hill 1991);
• PCA versus staff controlled delivery of pethidine (Zucker
1998);
• diclofenac versus placebo (Kostrica 2002);
• therapist versus control (Syrjala 1992; Syrjala 1995);
• relaxation and imagery therapy versus control (Syrjala
1992; Syrjala 1995);
• cognitive behaviour versus control (Syrjala 1992; Syrjala
1995);
• hypnosis versus control (Syrjala 1992; Syrjala 1995);
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• chlorhexidine versus salt and soda (Dodd 2000);
• ’magic’ (lidocaine solution, diphenhydramine
hydrochloride and aluminium hydroxide suspension) versus salt
and soda (Dodd 2000);
• sucralfate versus salt and soda (Dodd 2003);
• phenytoin mouthrinse versus placebo (Baharvand 2010).
Characteristics of outcome measures
Treatment of mucositis
Nine trials looked at whether the mucositis had improved (Chiara
2001; El-Housseiny 2007; Kaushal 2001; Kim 1985;Malik 1997;
Masucci 2005; Porta 1994; Schedler 1994; Schubert 1987) and
seven trials reported whether the mucositis was eradicated com-
pletely (Baharvand 2010; Chiara 2001;Dodd 2000; El-Housseiny
2007; Loprinzi 1997; Porta 1994; Wadleigh 1992). Three trials
looked at mild to moderate (rather than severe) mucositis (Barber
2007; Genot-Klastersky 2008; Kuhn 2009). Six trials reported the
mean number of days to heal the mucositis (Dodd 2000; Dodd
2003; Hejna 2001; Papila 2003; Porta 1994; Valcarcel 2000). Six
trials used WHO criteria for mucositis on a 0 to 4 scale, where
0 = none, 1 = erythema/soreness, 2 = ulcer and able to eat, 3 =
ulcer and limited eating, 4 = ulcer with haemorrhage and necrosis
(Cubukcu 2007; El-Housseiny 2007; Loprinzi 1997;Malik 1997;
Porta 1994; Wadleigh 1992). Two trials used NCI Common Tox-
icity Criteria (Baharvand 2010; Barber 2007), and a further trial
the EORTC scale (Genot-Klastersky 2008). Two trials used a scale
with no specific criteria as follows: none, slight, moderate and se-
vere mucositis (Kim 1985; Kostrica 2002). A final trial reported
the proportion of patients with an improvement in mucositis pain
(Schubert 1987). This trial was included with other trials which
dichotomised mucositis as improved or not.
Control of mucositis pain
Twelve of the 14 trials on pain control (Baharvand 2010; Coda
1997; Ehrnrooth 2001; Hill 1990; Hill 1991; Hill 1992; Kostrica
2002; Mackie 1991; Pillitteri 1998; Syrjala 1992; Syrjala 1995;
Zucker 1998) used a patient scored visual analogue scale, with
Dodd 2000 using a 0 (no soreness) to 10 (very sore) scale which
could be converted into a 0 to 100 scale, and Dodd 2003 a 0 to 3
scale.
The mean and standard deviations for mucositis pain were pre-
sented at different time points: average over 2 to 5 days (Coda
1997); daily up to 7 days (Dodd 2000); average for worst mu-
cositis (Dodd 2003); 7 and 14 days post radiotherapy (Ehrnrooth
2001); 7 and 14 days post start of treatment (Baharvand 2010);
daily up to day 9 (Hill 1990; Hill 1991; Hill 1992); daily up to
day 28 (Kostrica 2002); daily up to day 18 (Mackie 1991); daily
up to day 14 (Pillitteri 1998); average over 3 weeks (Syrjala 1992);
average from days 6 to day 16 (Syrjala 1995); mean pain score
over treatment (Zucker 1998). We decided to use the time point
7 days after the start of treatment for mucositis as these data was
available for most trials, otherwise we used the nearest time point
reported. Four trials presented data on mean morphine utilisation
(mg/hour) for day 7 (Hill 1990; Hill 1991; Hill 1992; Pillitteri
1998). Two trials presented the data in a different form, one as
mean mg of morphine/day averaged over each week of the trial
(Syrjala 1992) and a further trial presented the data as mg of mor-
phine/kg/hour (Mackie 1991).
Three trials reported the duration of the pain control therapy (Hill
1990;Mackie 1991; Pillitteri 1998).Only two trials reported other
outcome measures which were related to oral function and ability
to eat (Kim 1985; Malik 1997).
Risk of bias in included studies
A summary of the risk of bias assessments appears in Figure 1
and Figure 2. The concealment of allocation was adequate for
nine (28%) of the 32 trials and it was unclear for the remaining
23; in no trials was this considered inadequate. In seven trials
assessing pain the patient could not be blinded to the intervention.
The outcome assessor was blinded for 18 of the remaining 24
trials. Twenty-one trials gave a clear description of withdrawals
by trial group, this being unclear in the remaining trials. Letters
were sent to authors of the trials where clarification was needed
and seven replies were received (Dodd 2003; Hejna 2001; Hill
1990; Loprinzi 1997; Masucci 2005; Pillitteri 1998; Valcarcel
2000), with the information supplied changing the assessment of
concealed randomisation from unclear to adequate in five studies
(Dodd 2003; Genot-Klastersky 2008; Hill 1990; Hill 1991; Hill
1992).
The validity of each studywas assessed as at low, unclear or high risk
of bias. Four studies were rated as at low risk of bias (Coda 1997;
Dodd 2003; Genot-Klastersky 2008; Hill 1992), six assessed as
unclear (Barber 2007; Hill 1990; Hill 1991;Kuhn 2009; Masucci
2005; Pillitteri 1998) and the remaining 22 trials at high risk of
bias.
Effects of interventions
For the 32 trials included in the review 1505 patients were ran-
domised and provide data for this review. This comprised 1023
patients participating in the 20 trials investigating the effective-
ness of agents to treat mucositis and 718 in the 14 trials evaluating
pain relief, with some trials providing data for more than one of
these outcomes. The number of patients ranged from 6 to 71 per
treatment or control group.
Treatment of mucositis
The following comparisons only included one trial for one ormore
of the mucositis outcomes. As this review is concerned with the
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meta-analysis of trials we have summarised the data from single
trials below by indicating any which showed a significant benefit
for the active intervention (further data is given in Table 1):
• allopurinol versus placebo (Porta 1994: statistically
significant benefit in favour of allopurinol for improvement in
mucositis, eradication and time to heal);
• chlorhexidine versus salt and soda (Dodd 2000: no
statistically significant difference);
• debridement versus no debridement (Cubukcu 2007:
statistically significant benefit for debridement for days to
clinical resolution and decreased severity);
• Gelcaire versus sucralfate and mucaine (Barber 2007: no
statistically significant difference);
• GM-CSF (granulocyte macrophage-colony stimulating
factor) versus no treatment (Masucci 2005: statistically
significant benefit for improvement in mucositis at end of
radiotherapy);
• GM-CSF versus placebo (Valcarcel 2000: no statistically
significant difference);
• GM-CSF versus povidone iodine (Hejna 2001: statistically
significant benefit for GM-CSF for time to heal);
• GM-CSF versus antimycotic mouthrinse (Papila 2003:
statistically significant benefit for GM-CSF for time to heal);
• human placental extract versus Disprin™ (Kaushal 2001:
statistically significant benefit for human placental extract for
improvement in mucositis);
• ’magic’ (lidocaine solution, diphenhydramine
hydrochloride and aluminium hydroxide suspension) versus salt
and soda (Dodd 2000: no statistically significant differences);
• phenytoin mouthrinse versus placebo (Baharvand 2010:
statistically significant difference in quality of life at 7 days
favouring phenytoin);
• polyvariant intramuscular immunoglobulin versus placebo
(Schedler 1994: statistically significant benefit for the
immunoglobulin for improvement of mucositis);
• sucralfate versus salt and soda (Dodd 2003: no statistically
significant difference);
• tetrachlorodecaoxide versus placebo (Malik 1997: no
statistically significant difference);
• vitamin E versus placebo (Wadleigh 1992: no statistically
significant difference);
• vitamin E (topical) versus vitamin E (swallowed)
(El-Housseiny 2007: statistically significant benefit for the
topical vitamin E for improvement of mucositis).
The comparisons below include more than one trial for some of
the outcomes measured and the results of the meta-analysis are
presented:
Benzydamine HCl versus placebo
Two trials (Kim 1985; Schubert 1987) provided data (Analysis
1.1) for improvement in mucositis and there was no statistically
significant difference between benzydamine and placebo with risk
ratio (RR) 1.22 (95% confidence interval (CI) 0.94 to 1.60). Both
trials were assessed as at high risk of bias. Schubert 1987 noted a
lack of power in this study.
Sucralfate versus placebo
Two trials (Chiara 2001; Loprinzi 1997) provided data for eradi-
cation of mucositis (Analysis 3.1) and there was no statistically sig-
nificant difference between sucralfate and placebo with RR 1.13
(95% CI 0.66 to 1.94). One trial was assessed as at unclear risk of
bias, the other at high risk of bias.
Laser versus sham treatment
Two trials (Genot-Klastersky 2008; Kuhn 2009) provided data
(Analysis 2.1) for the outcome of mild to moderate mucositis and
there was a statistically significant benefit for the laser with RR
5.28 (95% CI 2.30 to 12.13). One trial was assessed as at low risk
of bias the other as at unclear risk of bias.
Control of mucositis pain
As above the comparisons below only included one trial for the
pain outcomes (further data given in Table 1):
• alfentanil versus morphine (Hill 1992: statistically
significant difference in favour of alfentanil for daily mean opiate
intake);
• hydromorphone versus morphine (Coda 1997: no
statistically significant difference);
• sufentanil versus morphine (Coda 1997: no statistically
significant difference);
• morphine versus tricyclic antidepressant (Ehrnrooth 2001:
statistically significant difference in favour of morphine for less
pain);
• sufentanil versus hydromorphone (Coda 1997: no
statistically significant difference);
• pharmacokinetically based patient controlled analgesic
infusion system (PKPCA) versus PCA for delivery of morphine
(Hill 1991: statistically significant difference in favour of
PKPCA morphine for less pain but more opiate per hour);
• PCA versus staff controlled delivery of pethidine (Zucker
1998: no statistically significant differences);
• phenytoin mouthrinse versus placebo (Baharvand 2010: no
statistically significant difference);
• diclofenac versus placebo (Kostrica 2002: no statistically
significant difference);
• relaxation and imagery therapy versus control (Syrjala
1995: no statistically significant difference);
• hypnosis versus control (Syrjala 1992: no statistically
significant differences);
• chlorhexidine versus salt and soda (Dodd 2000: no
statistically significant difference);
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• ’magic’ (lidocaine solution, diphenhydramine
hydrochloride and aluminium hydroxide suspension) versus salt
and soda (Dodd 2000: no statistically significant difference);
• sucralfate verus salt and soda (Dodd 2003: no statistically
significant difference).
The comparisons below include more than one trial for some of
the outcomes measured and the results of the meta-analysis are
given below:
Patient controlled analgesia (PCA) versus continuous
infusion delivery of morphine
Three trials (Hill 1990;Mackie 1991; Pillitteri 1998) provide data
for mean pain score (7 day data used for Pillitteri 1998) (Analysis
4.1; Analysis 4.2; Analysis 4.3). The meta analysis showed no
statistically significant difference in mean pain score with a mean
difference (on 0 to 100 scale) of -2.49 (95% CI -12.28 to 7.29).
The three trials also provided data for daily mean opiate intake
mg per hour and this outcome showed a statistically significant
reduction in mean opiate intake favouring the PCA morphine
group, with a mean difference (reduction) of 0.65 mg/hour (95%
CI 0.09 to 1.20) (P = 0.02). The trials also provided data on the
duration of pain control (days) and the meta-analysis showed a
statistically significant reduction in days of pain favouring PCA,
with a mean difference of -1.87 (95% CI -3.49 to -0.25) (P =
0.02). There was no evidence of heterogeneity between the effects
for the three studies for either mean opiate intake or duration (P
> 0.50, I2 = 0). However two of the three trials were assessed as
unclear risk of bias and one as at high risk of bias (Mackie 1991).
Therapist versus control
Two trials (Syrjala 1992; Syrjala 1995) provided data (Analysis 5.1)
for average pain score but the meta analysis showed no statistically
significant difference between the group who received therapist
visits and the control group who received treatment as usual, with
mean difference (on 0 to 100 scale) of -5.61 (95% CI -17.25 to
6.02). Both trials were assessed as at high risk of bias.
Cognitive behaviour therapy versus control
Two trials (Syrjala 1992; Syrjala 1995) provided data (Analysis
6.1) for average pain score and the meta analysis showed no sta-
tistically significant difference between the group who received
cognitive behaviour therapy and those who received treatment as
usual (control group) with mean difference (on 0 to 100 scale) of -
7.29 (95% CI -17.40 to 2.83). Both trials were assessed as at high
risk of bias.
D I S C U S S I O N
Oral mucositis is a common and painful complication of cancer
chemotherapy and radiotherapy. It can limit the tolerability of
therapy, leading to reductions in treatment and, therefore, poten-
tially limiting treatment efficacy (Kowanko 1998). This review
updates the evidence for the efficacy of interventions to treat mu-
cositis and another Cochrane review looks at the evidence for pre-
venting mucositis (Worthington 2007b).
Since our original reviews there has been an expansion of evidence
in this area of cancer care. The number and range of interventions
have increased. In addition, the last 5 years have seen increasingly
frequent reporting of outcomes other than the presence or absence
of mucositis. As a result, two new outcomes were included in our
previous update (2005) of this review: time taken to heal mucosi-
tis and duration of pain control therapy. Our current update in-
cludes a further outcome: the severity of mucositis. To reflect the
increased number and range of studies the review has been split
into two parts, one evaluating the effectiveness of agents to treat
mucositis and the other the management of pain associated with
the condition. There has been increasing recognition that other
endpoints, such as oral intake (ability to take fluids or solid food
by mouth), quality of life and duration of hospital stay, may be
clinically more relevant and more important to patients (Bellm
2002). Unfortunately, there was insufficient data to include these
more patient-oriented endpoints in this review nor was there data
on systemic infection and use of antibiotics. Whilst this latter out-
come is often cited as a possible consequence of mucositis it may
be due to other causes.
The broad scope of interventions included in this review indicate
the importance of this condition to clinicians and the uncertainty
of how to manage it optimally. The 32 trials included have re-
cruited 1505 patients and evaluated 27 different interventions. Of
all the interventions examined in this review only three mucositis
treatments were investigated by more than one trial and only one
comparison was significant for one outcome: low level laser treat-
ment was found to reduce the severity of mucositis. There were
only three comparisons for pain control which includedmore than
one trial, only one of which showed a statistically significant effect.
There was no evidence to suggest that there was a difference in
pain control between continuous infusion and patient controlled
analgesia (PCA). However, the PCA group required less morphine
than the continuous infusion group, and the pain lasted for 2 days
less.
For the remainder of the comparisons of treatment and pain con-
trol examined in this review, a lack of duplication of studies by
independent groups investigating the same interventions limits
the strength of evidence and generalisability of the results. Our
review agrees with two systematic reviews looking at antimicrobial
therapy (Donnelly 2003) and GM-CSF (Fung 2002) for the pre-
vention and treatment of oral mucositis. There is no clear pattern
emerging regarding the benefit or otherwise of antimicrobial use
to manage mucositis. Studies looking at GM-CSF are limited and
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the use of GM-CSF cannot currently be recommended for the
treatment of mucositis.
Several issues identified in this review may have affected the valid-
ity of the results. The setting of the included trials varied with the
majority being conducted by medical teams who did not report
any involvement with a dentist or hygienist (68%). None of the
trials assessed the reliability of the outcomemeasures used, particu-
larly with regard to the presence or absence of oral candidiasis. The
appearance of mucositis and oral candidiasis can be similar; lead-
ing to potential mis-diagnosis if the assessors were not sufficiently
trained or experienced in the diagnosis of these oral lesions. Several
different scoring systems were used to assess mucositis severity and
in some studies the scoring systems were not defined. This vari-
ability may have led to discrepancies between studies. Accepting
that caveat, there was consistency in the number of categories used
and in every case the lowest score indicated no mucositis. Only
four of the included studies reported power calculations a priori
(Genot-Klastersky 2008; Loprinzi 1997; Masucci 2005) and one
trial reported a post hoc power calculation as an explanation for
their findings (Schubert 1987). It is possible that some studies
which found no difference between treatments compared were
underpowered. With respect to publication bias, several negative
studies for mucositis have been reported and we congratulate the
authors and editors for doing so. It was not possible to detect any
existing publication bias, as there were insufficient studies in each
meta-analysis investigating the same interventions.
The country of conduct, financial support and the design of trials
varied greatly between studies. It was especially unfortunate that six
studies presented data in an unusable form.We feel that the use of
structured abstracts and adherence to the Consolidated Standards
of Reporting Trials (CONSORT) guidelines will greatly improve
the reporting and hopefully the conduct of randomised controlled
trials (RCTs) (Begg 1996; Moher 2001).
For patients being treated for cancer the decision-making around
giving potentially toxic therapy to prevent mucositis versus treat-
ing mucositis once it is established can be a clinical dilemma. Our
recent review of interventions to prevent mucositis identified a
small number of interventions with weak, unreliable evidence of
benefit. This review of therapies for established mucositis shows
limited evidence, from two small trials including a total of 57 par-
ticipants, that low level laser treatment reduced mucositis severity,
and unreliable evidence that opiate delivered by PCA results in a
lower total dose of opiate, and improved duration of pain control
compared to delivery by a continuous infusion. Given the pain
and inconvenience that mucositis causes to a population of pa-
tients receiving treatment for cancer it is important that further,
well designed, RCTs should be conducted investigating new treat-
ments for the management of mucositis and new ways of con-
trolling pain. Future studies should include more patient-oriented
outcomes in addition to measures of mucositis severity.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is limited evidence that low level laser treatment is bene-
ficial in reducing the severity of mucositis. There is no evidence
that patient controlled analgesia is better than continuous infusion
method for controlling pain. However there is unreliable evidence
that less opiate is used per hour, and the duration of pain is slightly
reduced with patient controlled analgesia.
Implications for research
There is a need for further, well designed trials, preferably includ-
ing a placebo or no treatment control, assessing the effectiveness of
interventions considered in this review and new interventions for
managing oral mucositis. These should be reported according to
the CONSORT guidelines. Consideration should be given to the
adoption of standard clinical outcome measures, the development
of patient based outcome measures and inclusion of the cost of
the interventions.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Baharvand 2010
Methods Location: Iran.
Number of centres: Multicentre.
Funding source: Unclear.
Recruitment period: December 2006 to May 2007.
Participants Inclusion: Adults undergoing chemotherapy who developed oral mucositis Gr 2 or worse,
with no other systemic disease, life expectancy at least 6 months
Exclusion: Other concomitant disease, heavy smoker, severe psychological disorder
14 randomised, 12 completed.
Interventions GpA (6) Phenytoin, 0.5% (50:50 mixture sodium phenytoin and phenytoin powder), 10 ml
given 4 times daily, swished around mouth and spat out
GpB (6) Placebo 10 ml 4 times daily, swished around mouth and spat out
Outcomes Assessed at baseline, 1 week and 2 weeks after start of treatment
VAS scores for pain, Mucositis score NCI Common Toxicity Criteria (0 to 4 scale), duration
of mucositis (not used as data presented in a format not suitable for pooling)
Notes No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Patients were assigned to case and control
groups randomly and separately at each de-
partment. Sampling method was performed
on a multi-central, non-probable (easy to ac-
cess) basis.’
Allocation concealment? Unclear Not mentioned.
Blinding of participants/carers? Yes Patients and nurses blinded to treatment
group.
Blinding of outcome assessors? Unclear Ppatients self assessed pain and QoL, unclear
who conducted the mucositis assessments
Incomplete outcome data addressed? Unclear 2/14 randomised were subsequently excluded
because they were ’uncooperative’ - no details
given. It is not stated which group these were
from, but if both exclusions were from the
same group, this would represent 25% drop
out from that group and a significant risk of
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Baharvand 2010 (Continued)
bias
Free of selective reporting? Yes Reported mucositis scores, duration of mu-
cositis, pain and quality of life
Free of other bias? Yes
Barber 2007
Methods Location: United Kingdom.
Number of centres: Two.
Funding source: Not stated.
Recruitment period: September 2004 to April 2005.
Participants Adults aged 18 years and over, with at leastGrade 1OMandwhen they felt theywere no longer
receiving adequate pain control via simple analgesic, receiving daily doses of radiotherapy to
the head and neck
20 eligible, 20 randomised.
Interventions GpA (10) Gelclair, 4x in the 24 hour study (30 min to 1 hour before eating/drinking and
before bedtime, swished around mouth and spat out)
GpB (10) Standard care 10 ml 4x in 24 hour study (30 min to 1 hour before eating/drinking
sucralfate and Mucaine swished around mouth and swallowed) (30 min to 1 hour before
eating/drinking)
Outcomes Assessed at baseline, 1 hour, 3 hours and 24 hours post treatment
VAS scores for pain (not used as only 24 hour assessment), Pain on speaking, Mucositis score
NCI Common Toxicity Criteria (0-4 scale)
Secondary outcome - extent to which ability to swallow is influenced by pain (odynophagia)
Notes Outcomes assessed by nurse specialists blinded to group allocation. No power calculation
reported
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “computer generated random alloca-
tion sequence for the 2 centres was prepared
by Exeter clinical research radiographer”
Allocation concealment? Yes Quote: “radiographer accessed the randomi-
sation list by telephone to determine the pa-
tients group allocation”
Blinding of participants/carers? No Comment: Not possible to blind patients and
carers because one product ’swish and spit’
and the other ’swish and swallow’
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Barber 2007 (Continued)
Blinding of outcome assessors? Yes Quote: “single blind trial with the administer-
ing nurse specialist being unaware as to what
medication had been issued”
Incomplete outcome data addressed? Yes Quote: “one patient despite their eagerness
to participate fell asleep during the course of
the trial and did not take their Sucralfate and
Mucaine before the 24-h assessment” “The
missing 24-h scores were substituted with 3-
h assessment scores”
Comment: Unlikely to influence results.
Free of selective reporting? No Comment: Despite intention to report mu-
cositis it was not reported apart from at base-
line
Free of other bias? Unclear Small pilot study which lacks power. At base-
line there are differences between the groups
that may have influenced the results. Inter-
vention group had more severe OM (6/10 vs
3/10), and included all patients with enteral
feeding and support. 3/10 in control group
and 1/10 of intervention group had concomi-




Number of centres: One.
Funding source: Not stated.
Recruitment period: Not stated.
Participants Inclusion: Adults with histopathologically confirmed diagnosis of malignancy, WHO per-
formance status </=2 chemotherapy induced stomatitis at any time during chemotherapy
treatment with any antiblastic drug alone, or in combination
Exclusion: Previous or concomitant radiotherapy to oral mucosa
40 enrolled and randomised, 34 completed.
Interventions GrA (n = 20) sucralfate gel (1 gr) (5 ml) applied over mucosa, 3 times daily. Evaluated after
1 or 2 weeks and at time of next course of chemotherapy
GrB (n = 20) placebo (in identical sachets with identical taste, colour and consistency to
sucralfate) (5 ml) applied over mucosa, 3 times daily. Evaluated after 1 or 2 weeks and at time
of next course of chemotherapy
Outcomes Complete response to treatment, VAS scores for pain but data not reported. Mucositis not
resolved at 14 days is used
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Notes “No sample size was calculated”.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear ’Randomised’ no further details given.
Allocation concealment? Unclear Not reported.
Blinding of participants/carers? Yes Quote: “....double blind placebo controlled..
..”
Quote: “Drug or placebo were provided in
individual sachets of 5 ml with identical taste,
colour and consistency”
Blinding of outcome assessors? Yes Quote: “....double blind placebo controlled..
..”
Incomplete outcome data addressed? Yes Withdrawals and exclusions clearly described
and balanced in each group (2 in each group
non-compliant and 1 in each group withdrew
due to taste disturbances). 15% lost to follow
up
Free of selective reporting? Yes Eradication and improvement ofmucositis re-
ported.
Free of other bias? Unclear No information on funding.
Coda 1997
Methods Location: Seattle, USA.
Number of centres: One.
Funding source: Not stated.
Recruitment period: March 1991 to July 1993.
Eligible patients had oral mucositis and had been on opioids for at least 2 days
Participants Inclusion: Patients undergoing bone marrow transplant for haematological malignancies or
breast cancer, who were treated with total body irradiation or busulphan, who developed oral
mucositis and stayed on study for at least 2 days
Exclusion: History of adverse reaction to opioid analgesics, moderate to severe hepatic, renal
or pulmonary diseases, those currently taking opioids for other purposes, history of opioid,
alcohol or cocaine abuse
119 enrolled and randomised, 97 completed at least 2 days of treatment
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Coda 1997 (Continued)
Interventions Gr A (n = 39) Patient controlled analgesia (PCA) morphine 5 mg/ml for at least 2 days
Gr B (n = 40) PCA hydromorphone 1 mg/ml for at least 2 days.
Gr C (n = 40) PCA sufentanil 5 µg/ml for at least 2 days.
In all groups PCA was set to deliver bolus doses equivalent to 15 µg/kg morphine sulphate,
with a 10 min lockout period. If increasing the demand for bolus doses was not sufficient to
control pain, a baseline continuous infusion (CI) was added at a rate of approx 50% of the
average rate during the previous 24 hour period. Patients were given the option of a higher
CI rate during the night in order to minimise the demand for bolus doses during sleep
Outcomes Average pain VAS score (0 to 100) for days 2 to 5. Number who discontinued as drug not
working
Notes No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “....randomised using a computer gen-
erated randomisation scheme”
Allocation concealment? Yes Not reported.
Blinding of participants/carers? Yes Quote: “....randomised double blind study”.
Quote: “study opioids were supplied by the
pharmacy service and were coded 30 ml PCA
vials that were labelled 5mg/mlmorphine sul-
phate”
Blinding of outcome assessors? Yes Quote: “....randomised double blind study”.
Incomplete outcome data addressed? Unclear 19/119 (16%) patients randomised had < 2
days of treatment and were therefore not con-
sidered evaluable (9, 6 & 4 in groups A, B &
C respectively). See below
Of the 100 patients who had at least 2 days of
treatment, 69/100 completed the study and a
further 31/97 were excluded - 11 due to side
effects of treatment (2, 6 & 3 in groups A, B
& C respectively), 8 due to inadequate pain
relief (1, 0 & 7 respectively) and 12 due to
BMT complications (1, 5 & 6 respectively)
for total withdrawal/exclusion rates of ran-
domised participants of 13/39 (33%), 17/40
(43%) and 20/40 (50%) in groups A, B & C
respectively
Results are reported for the ’evaluable’ pa-
tients (30, 34 & 36 in groups A, B & C re-
25Interventions for treating oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Coda 1997 (Continued)
spectively)
Free of selective reporting? Yes Many outcomes described and reported.
Free of other bias? Unclear Baseline characteristics given for ’evaluable’
patients only. Some randomised patients had
less than 2 days treatment and were excluded
because they did not develop mucositis (4, 1
& 2 in groups A, B & C), stopped treatment
due to side effects (4, 1 & 2 in groups A, B
& C), protocol violation (1, 3 in groups A &
B) or died (1 in Gr B). Likely that prognostic





Number of centres: One.
Funding source: Not stated.
Recruitment period: February 2002 to September 2005.
Participants Children aged 1 to 14 years with solid tumours, hospitalised for induction chemotherapy,who
had large contiguous oral mucositis lesions, neutrophil count </= 1000/mm3, were taking
systemic opioids and prophylactic antibiotics.
40 eligible, 40 randomised.
Interventions Gp A (n = 20) Debridement of oral lesions + standard care.
Gp B (n = 20) Standard care only.
Outcomes Time to complete healing of lesions, mean mucositis scores at 6 days using WHO scale. 0 to
3 scale for pain included opiate use and presence of ulcers so not used in meta analysis. No
specific information given on withdrawals or losses to follow-up. Oral assessments conducted
by two trained calibrated dentists. Can only report results without using the data
Notes Outcome data collected by oral examinations performed by ’two calibrated dentists’ three
times per week. Total number of oral examination performed was 960 in Gp A and 980 in
Gp B. No power calculation reported
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Children were randomly assigned....
”
Quote: “....were assigned one by one into two
groups according to the intervention admin-
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istered”
Comment: Unclear as to method of sequence
generation - possibly alternation?
Allocation concealment? Unclear Not reported.
Blinding of participants/carers? No Not really possible to blind patients or carers.
Blinding of outcome assessors? Unclear Not mentioned.
Incomplete outcome data addressed? Unclear No information given.
Free of selective reporting? Unclear No information given.
Free of other bias? Unclear Groups well balanced at baseline. Unclear
funding.
Dodd 2000
Methods Location: San Francisco, USA.
Number of centres: Not stated (23 referral centres).
Funding source: Chlorhexidine mouthwash provided by Proctor and Gamble
Recruitment period: Not stated.
Patient had mucositis confirmed by clinician.
Participants Inclusion: Adults over 18 years, undergoing stomatotoxic chemotherapy, who could read &
write English, were mentally capable of understanding research protocol, had Karnofsky Per-
formance Status >/= 60%. Eilers Oral Assessment Guide score >/=10, and physician assessed
& documented oral mucositis
Exclusion: Concurrent RT to head & neck, diagnosed with AIDS or leukaemia, undergoing
bone marrow transplant
299 eligible, 200 randomised, 142 completed.
Interventions Gr A Chlorhexidine mouthwash 0.12% 20 ml in mouth, swish for 20 seconds, 4 times/day
for 12 days
Gr B Salt & Soda mouthwash (1 teaspoon each in 1 pint water) 20 ml in mouth, swish for
20 seconds, 4 times/day for 12 days
Gr C Magic mouthwash (lidocaine 0.5%, diphenhydramine HCL 0.25 ml, Aluminium hy-
droxide 14.75 ml) 20 ml in mouth, swish for 20 seconds, 4 times/day for 12 days
All patients were instructed in PROSELF Mouth Aware (PSMA) programme of oral hygiene
- new toothbrush for each CT cycle, regular & thorough brushing, daily flossing, regular oral
assessment using Oral Assessment Guide, training to recognise mouth lesions requiring nurse
assessment
Outcomes Patient soreness rating on 0 (no soreness) to 10 (very sore) scale for 7 days, day 7 used.
Mucositis oral assessment guide used by patients dichotomised as eradicated or not. The mean
time to cessation of symptoms (SD) is also used
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Dodd 2000 (Continued)
Notes 0 to 10 scale converted VAS scale to 0 to 100. No power calculation reported
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ’randomised double blind clinical
trial“.
Allocation concealment? Unclear No information given.
Blinding of participants/carers? Yes Quote: ’double blind’.
Quote: ”Intervention nurses who performed
initial oral assessments and the telephone con-
tacts with the patients were blind to the group
assignments“
Comment: Although one mouthwash con-
tained a suspension and caused oral numb-
ness, one caused discolouration of teeth &
gums and one clear solution we consider it to
be blind
Blinding of outcome assessors? Yes Quote: ’double blind’.
Comment: Outcomes assessed by patients.
Incomplete outcome data addressed? No 58/200 (29%) of those randomised were ex-
cluded. 47 (24%) because they were hos-
pitalised, too nauseated, too ill, or didn’t
like taste or numbness caused by mouthwash
(likely to be more unwell that those included)
A further 11 patients took more than 12 days
to report cessation of OM symptoms. The
treatment group allocation of these 58 is not
given but ”no significant difference in demo-
graphic characteristics between 142 patients
who reported cessation of signs & symptoms
of mucositis within 12 days and those who
didn’t .... and proportion similar in 3 mouth-
wash groups (P = 0.52)
Free of selective reporting? Unclear Comment: Pain can only be measured by the
patient which is subjective. No other out-
comes reported
Free of other bias? Unclear Unclear.
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Dodd 2003
Methods Location: San Francisco, USA.
Number of centres: Two.
Funding source: Oncology Nursing Foundation, Sigma theta Tau International, Reserach
Centre for Symptom Management at UCSF, School of Nursing
Recruitment period: Unknown.
Participants Adults who were initiating radiotherapy for head and neck cancer were invited to participate
and were randomised when mucositis developed
Inclusion: > 18 years, able to read and understand English, Karnofsky Performance Status >/
= 60%, mentally capable of giving informed consent
35 eligible, 33 enrolled, 30 completed.
Excluded: AIDS, previous radiotherapy to head & neck, previous chemotherapy
Interventions Gr A (n = 14) micronised sucralfate, 1 g/15 ml mouthwash. Patients instructed to swish and
spit 4 times daily after meals and at bedtime
Gr B (n = 16) Salt and soda Mouthwash (1 teaspoon each of salt and sodium bicarbonate to
a pint of water). Patients instructed to swish and spit 4 times daily after meals and at bedtime
Outcomes Mean healing time in days is used. Pain (swallowing) at end of RT and at 1 month, and pain
intensity (0 to 3 scale) at time of worst mucositis which was used. Breaks in RT
Notes MacDibbs score for mucositis (mean and SD). Breaks in RT. No sample size calculation
reported
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Comment: No details given in paper. Cor-
respondence from author that randomisation
was by computer generated random numbers
Allocation concealment? Yes Comment: Correspondence from author - al-
location was concealed in opaque sealed en-
velopes. Mouthwashes packaged in opaque
bottles
Blinding of participants/carers? Yes Quote: “Double blind”.
Blinding of outcome assessors? Yes Quote: “Double blind”.
Incomplete outcome data addressed? Yes 3/33 (9%) dropped out - not stated which
group these patients were in, but is unlikely
to affect results
Free of selective reporting? Yes Planned outcomes described and reported.
Free of other bias? Unclear Unclear.
29Interventions for treating oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ehrnrooth 2001
Methods Location: Denmark.
Number of centres: One.
Funding source: Not stated.
Recruitment period: January 1995 to January 1999.
Participants Inclusion: Adults undergoing radiotherapywith curative intent for head&neck cancer (biopsy
verified squamous cell carcinoma of larynx, pharynx or oral cavity) with radiation induced
pain not managed with acetaminophen
Exclusion: Cancer related pain before the initiation of radiotherapy, ongoing treatment with
opioids, tricyclics, or non-steroidal anti-inflammatory drug, or known contraindications to
tricyclics
86 eligible, 43 enrolled and randomised and 39 completed.
Interventions Gr A (n = 22) oral morphine chloride (5 mg x 6) additional doses of 5 mg each, plus stimulant
laxative
Gr B (n = 21) oral nortriptyline (tricyclic antidepressant) (25mg x 2). Patients on nortriptyline
had the dose increased by 25 mg every second day, until pain relief or intolerable side effects
were experienced (up tomax dose of 150 mg/day). Acetaminophen was used for breakthrough
pain in nortriptyline group
Patients with insufficient pain relief were offered supplementarymedication from the opposite
treatment arm
Outcomes VAS pain scores at 1, 2 weeks after randomisation and 2 weeks after end of radiotherapy. The
7 day scores are used
Notes Danish version of McGill Pain Questionnaire.
Sample size calculation reported: to detect a 10 mm difference in VAS score for pain (smallest
clinically significant difference) assuming a standard deviation of 0.2 in VAS score, with α =
0.05 and β = 0.1 a total of 43 patients was required to detect this difference
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “’in a randomised design”.
Allocation concealment? Unclear No information given.
Blinding of participants/carers? No Different frequency for interventions.
Blinding of outcome assessors? No Not mentioned.
Incomplete outcome data addressed? Yes Post randomisation exclusions and with-
drawals described and reasons given. Equal
numbers in both groups. Two patient in each
arm considered in evaluable. 9% lost to fol-
low-up
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Free of selective reporting? Yes Primary and secondary outcomes described
and reported.
Free of other bias? No Patients with insufficient pain relief were of-
fered supplementary medication from the
other treatment arm. 11/21 (52%) of patients
in Gr2 had morphine as well as nortriptyline
(mean time to morphine 13.4 +/- 8.4 days).




Number of centres: One (one treatment centre but two recruitment centres)
Funding source: Not stated.
Recruitment period: Not stated.
Participants Children under 12 years with mucositis, cancer type unclear but receiving chemotherapy. 80
eligible, 80 randomised (40 to each group), 63 completed
Interventions Gp A 100 IU Vitamin E capsule either emptied into mouth or chewed, twice daily
Gp B 100 IU Vitamin E capsule swallowed twice daily.
Outcomes Mucositis severity scores by WHO criteria, improvement of mucositis at 5 days
Notes No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “patients were randomly assigned”.
Allocation concealment? Unclear No mention of allocation concealment.
Blinding of participants/carers? No One group were instructed to swallow cap-
sule, the other group instructed to either chew
it or have contents emptied into mouth by
carer
Blinding of outcome assessors? No Not mentioned.
Incomplete outcome data addressed? No In Gp A 3 patients non compliant with treat-
ment, 6 died & 3 lost to follow-up (30% ex-
cluded from analysis), in Gp B 2 patients non
compliant with treatment (analysed in Gp A)
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, 2 died & 3 lost to follow-up (18% excl from
analysis). Data analysed on 28/40 (70%) pa-
tients randomised to Gp A plus the 2 from
Gp B, and 33/40 (83%) randomised to Gp B.
Possible that incomplete outcome data may
have influenced results
Free of selective reporting? Unclear Comment: Planned to follow patients fol-
lowed for 5 days. Comment in discussion that
some of the Gp B patients ’improved later’,
suggesting that the relative effects may be dif-
ferent after longer follow-up
Free of other bias? No Comment: Differences between groups at
baseline. Severity of mucositis (Gp A median
severity score 3, Gp B median severity score
2). Distribution of mucositis sites different in
each group
“On treatment” analysis, more patients ex-
cluded from analysis in Gp A, and non com-
pliant patients in Gp B added to Gp A
Genot-Klastersky 2008
Methods Location: Belgium.
Number of centres: One.
Funding source: Not stated.
Recruitment period: Not stated.
Two studies reported, one prevention and one treatment of OM
Participants Adults with haematological malignancies and grade 1 or 2 OM induced by chemotherapy +/
- radiotherapy prior to stem cell transplantation. 37 patients seemed eligible, 36 randomised,
18 to each group
Interventions GpA (18) low energy laser (LEL) on alternate working days (approx 3 sessions of 6 mins per
week delivering 2 J/cm2 to each lesion)
GpB (18) sham illumination (laser switched off ) on alternate working days (approx 3 sessions
of 6 mins per week)
Outcomes Primary - time to development of grade 3 OM using EORTC scale
Secondary - success of treatment (no lesions >/= Gr 3).
Number with grade 3 OM after 7 days.
Notes 3 additional outcome measures added retrospectively: development of oesophageal mucositis,
presence of diarrhoea, development of septicaemia
Sample size calculation for expected rates of OM at 7 days of 10% intervention and 60%
control, 20 patients per group will give 90% power for 2-sided log rank test and significance
level of 5%
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “Randomised”. Clarified by e-mail
from authors.
Allocation concealment? Yes Not mentioned but clarified as sealed en-
velopes in e-mail from authors
Blinding of participants/carers? Yes Therapists and nurses doing pretreatment as-
sessments not blinded (for safety/ethical rea-
sons), but patients were blinded
Blinding of outcome assessors? Yes Quote: “independent qualified healthcare
professional observer (blinded to the treat-
ment administered)”
Incomplete outcome data addressed? Yes Outcome data complete for primary and sec-
ondary outcomes. 1 patient missing from ret-
rospective outcome data in each group. 6%
loss to follow-up
Free of selective reporting? Yes Planned primary and secondary outcomes re-
ported as well as additional retrospectively
added outcomes. Acknowledged the ’method-
ological limitation not to have planned this
data collection and analysis at the beginning
of the trial’
Free of other bias? Yes Comment: All patients analysed in the groups
to which they were randomised (ITT) and
groups were comparable at baseline - so prob-
ably
Hejna 2001
Methods Location: Vienna, Austria.
Number of centres: One.
Funding source: Not stated.
Recruitment period: March 1998 to June 1999.
Participants Inclusion: PatientswithWHOgrade 1 to 3oralmucositis following5 FUbased chemotherapy.
Patients were > 19 years of age, could read & understand German, had WHO Performance
Status < 3
Exclusion: History of adverse reactions to G-CSF, or GM-CSF, or iodine, severe concomitant
diseases including hyperthyroidism, dermatitis herpetiformis or need for systemic G-CSF or
GM-CSF for neutropenia
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31 recruited and randomised and completed.
Interventions Gr A (n = 15) GM-CSF (Malgramostim) mouthwash three times daily (400 ugmolgramostim
dissolved in 250 ml water. Patients were instructed to wash mouths with 25 ml and keep in
mouth for 3 min, then rinse and repeat 10 times within 30 mins)
Gr B (n = 16) Antiseptic mouthwash (Povidone iodine) 4 ml povidone-iodine in 125 ml
water was used 6 times daily. This was kept in mouth for 3 mins. Patients received 4 daily
tablets of amphotericin B, 10 mg (AA regimen)
All patients with oral mucositis exceeding grade 2 were offered topical lidocaine 6 times daily
Outcomes Mean duration of therapy until complete remission.
Notes No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Randomisation performed without
stratification according to a balanced block
randomisation procedure carried out by a
third investigator”
Allocation concealment? Unclear No details given.
Blinding of participants/carers? No Quote “ Physicians were not blinded but the
patients were as to the efficacy of any of the
chosen regimes”
Comment: Different mouthwashes for differ-
ent frequencies plus only one group received
amphotericin B tablets
Blinding of outcome assessors? No Quote “ Physicians were not blinded but the
patients were as to the efficacy of any of the
chosen regimes”
Incomplete outcome data addressed? Unclear All patients completed. 2/16 (12%) patients
in control group did not provide final OM
score
Free of selective reporting? Unclear Unclear.
Free of other bias? No Significant differences between groups at
baseline for the following prognostic factors
age group, WHO performance status, smok-
ing status, oral hygiene. May have influenced
results. 4 patients in control arm did not re-
ceive treatment but ITT analysis conducted
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Hill 1990
Methods Location: Seattle, USA.
Number of centres: One.
Funding source: Pogramme project grant for National Cancer Institute and assistance from
Abbott Laboratories
Recruitment period: November 1985 to January 1987.
Participants Inclusion: Adults aged 18 to 50 years with acute lymphhatic leukaemia, acute non-lym-
phatic leukaemia, chronic myeloid leukaemia, Hodgkins or non-Hodgkins lymphoma or pre-
leukaemic syndrome undergoing high dose chemotherapy and total body irradiation prior
to bone marrow transplant. Patients had severe oral mucositis and remained on study for a
minimum of 7 days
Exclusion: History of drug abuse, unable to understand English, life threatening cardiac,
hepatic or renal disease
84 randomised, 58 completed.
Interventions Gr A Patient Controlled analgesia - morphine (PCA) 2 to 5 mg loading dose with 1 mg
bolus & lockout of 10 min. Bolus dose adjustment up to 5 mg available, & lockout could
be reduced to 5 minutes as treatment progressed. maximum allowable dose 60 mg/hour. At
night PCA patients had a continuous infusion set at the mean hourly rate of morphine for
the previous day shifts (16 hours). Minimum 7 days of treatment
Gr B Continuous infusion (CI) morphine - adjusted by nurses at patient’s request. Minimum
7 days of treatment
Minimum of 9 days.
Outcomes Average pain VAS score (0 to 100) for day 7. Daily mean morphine intake day 7. The mean
duration of morphine (days) - we are assuming that the standard errors not the standard
deviations are presented here
Notes No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ’Assigned randomly’ is stated in paper. Per-
sonal communication from study investigator
states that randomisation was computer gen-
erated by the Statistics department
Allocation concealment? Yes Randomisation generated by third party -
probably adequate. Confirmed by author
Blinding of participants/carers? No Comment: Interventions given differently.
Blinding of outcome assessors? Unclear Comment: Patients self assessed pain; hy-
gienist completed mucositis ratings unclear if
blinded
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Incomplete outcome data addressed? Yes 14/40 and 12/40 excluded from PCA and
CI groups respectively, because they were on
study for less than 7 days. Reasons given and
balanced in both groups 31 % follow-up
Free of selective reporting? Yes Comprehensive.
Free of other bias? Unclear Unclear.
Hill 1991
Methods Location: Seattle, USA.
Number of centres: One.
Funding source: National Cancer Instiute grant (CA38552) and National Institute on Drug
Abuse grant (DA 05513). Abbott Laboratories supplied the PCA infusers and drug supplies
Recruitment period: Not stated.
Randomised but not blind. Eligible patients had severe oral mucositis pain. Clear information
on withdrawals. 35% lost to follow-up
Participants Inclusion: Adults with acute lymphocytic leukemia, acute non-lymphocytic leukemia, chronic
myelogenous leukemia, Hogkin’s and non-Hodgkin’s lymphoma or preleukemic syndrome
planned to undergo bone marrow transplant. 54 eligible, 54 enrolled, 35 completed
Interventions Gr A (n = 31) PCA Morphine bolus 1 to 2 mg morphine sulphate as bolus, with 10 min
lockout
Gr B (n = 23) PKPCA (pharmacokinetically based patient controlled analgesic infusion sys-
tem). Individual pharmacokinetic profiles for morphine were determined on the day prior to
bone marrow transplant. 75 µg/kg dose was administered and venous blood samples taken
over following 8 hours to determine PK profile, and this information was used to tailor the
individual dose for the PKPCA intervention
Outcomes Average pain VAS score (0 to 100) for each study day, day 7 used. Mean opiate use mg/hour
for day 7. Severity of mucositis assessed by dental hygienist
Notes Data obtained from graphs. No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “randomly assigned”. Author clarified
this.
Allocation concealment? Yes No information given but clarified by corre-
spondence with author
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Hill 1991 (Continued)
Blinding of participants/carers? No Comment: Unblinded patients self assessed
pain; nurse assessment of amount morphine,
hygienist completedmucositis ratings unclear
if blinded
Blinding of outcome assessors? Unclear Comment: Unblinded patients self assessed
pain; nurse assessment of amount morphine,
hygienist completedmucositis ratings unclear
if blinded
Incomplete outcome data addressed? Yes 19/54 (35%) of those randomised were ex-
cluded, 11/31 (35%) from Gr A and 8/23
(35%) from Gr B. Reasons for each with-
drawal given in table 2
Free of selective reporting? Yes Planned outcomes described and reported.
Free of other bias? Unclear Unclear.
Hill 1992
Methods Location: Seattle, USA.
Number of centres: One.
Funding source: Not stated.
Recruitment period: Not stated.
Participants Inclusion: Adult patients undergoing bone marrow transplant for haematological malignan-
cies, who required treatment for oral mucositis pain
28 completed at least 4 days.
Interventions Gr A Morphine by Pharmacokinetically based patient controlled analgesic infusion system
(PKPCA)
Gr B Alfentanil (PKPCA).
In both groups patients had individual pharmacokinetic profile for the assigned opioid de-
termined prior to start of the study. A bolus dose of either 75 µg/kg morphine or 15 µg/
kg alfentanil was given followed by venous blood sampling over the following 8 hours, to
measure plasma drug concentrations. These data were then fitted to tri or bi exponential
functions and the function providing the best fit for each patient was used in the computer
program for calculations of infusion rates for that patient during therapy, providing a dose
tailored to give optimum plasma concentrations of opioid for each individual
Outcomes Average pain VAS score (0 to 100) for days 1 to 14, day 7 taken. Mean opiate use mg/hour
for day 7
Notes Standard deviations calculated from graphs. No power calculation reported
Risk of bias
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Hill 1992 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote “random assignment patient blind as-
sessment”.
Allocation concealment? Yes No information given but clarified by corre-
spondence with author
Blinding of participants/carers? Yes Quote “random assignment patient blind as-
sessment”. Provider not blinded
Blinding of outcome assessors? Unclear Patients self reported pain. Mean opiate use
calculated by computer
Incomplete outcome data addressed? Yes All patients included in pain scores and opioid
consumption. 0% drop-outs
Free of selective reporting? Unclear Unclear.
Free of other bias? Unclear Quote “Although significant bias was evident
in several patients in group 5/16 formorphine
and 8/12 for Alfentanil....”
Kaushal 2001
Methods Location: India.
Number of centres: One.
Funding source: Not stated.
Recruitment period: August 1997 to March 1999.
Participants Inclusion: Adults who developed oral mucositis after radiotherapy for histologically proven
squamous cell carcinoma of head and neck
Exclusion: Patients with early head and neck cancer suitable for brachytherapy, those on
palliative radiotherapy, had previous radiotherapy of chemotherapy, those with concurrent
chemotherapy or those with distant metastases
120 randomised and completed.
Interventions Gr A (n = 60) Human placental extract (Placentrex) 2 ml IM, 5 times weekly for 3 weeks
Gr B (n = 60) Disprin™ gargle, 1 tablet in a cup of water, 3 times daily 0.5mg/ml betametha-
sone oral drops, 8 drops 3 times daily
Both groups received Betadine™ antiseptic mouthwashes three times daily
Outcomes Progressionofmucositis to grade 3, improvement in dysphasia, decrease in pain (data not used)
. All evaluated 2 times weekly, but unclear over what time period. Interruption of radiotherapy
due to severe radiation reactions. To include the data we included the patients who did not
get worse with the mucositis improved outcome
38Interventions for treating oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kaushal 2001 (Continued)
Notes No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomised” - no details given.
Allocation concealment? Unclear No information given.
Blinding of participants/carers? No Comment: Interventions given differently.
Blinding of outcome assessors? No Not mentioned.
Incomplete outcome data addressed? Yes All randomised patients included in analysis.
0% drop-outs.
Free of selective reporting? Unclear Planned outcomes described and reported.
Free of other bias? Unclear Placentrex given for 3 weeks - ?duration of
control group treatment
Kim 1985
Methods Location: New York, USA.
Number of centres: One.
Funding source: DuPont Pharmaceuticals provided the medications used in the trial
Recruitment period: Not stated.
Randomised, double blind. Patients who complained of mouth or throat pain were eligible.
Unclear information on withdrawals. 60% lost to follow-up
Participants Adults with head and neck cancer receiving radiation therapy to oral pharyngeal regions,
complaining of throat or mouth pain.
67 randomised, 37 received benzydamine and 30 placebo. Results for mucositis given for days
2/3, for 33 in benzydamine and 28 in placebo groups, with loss to follow-up of 11% and 7%
respectively
Interventions Gr A Benzydamine chloride rinse/gargle 1.5 mg/ml used every 3 hours during the day
Gr B Placebo.
Outcomes Improvement in mucositis up 2/3 days, assessed by clinician. Specific criteria not given but
mucositis is presented on 1 to 4 scale with 1 = none, 2 = slight; 3 = moderate and 4 = severe. At
baseline there were 2 patients in the benzydamine group and 1 patient in the placebo group
with no mucositis and these patients have been excluded from our analysis. We dichotomised
4 point scale as mucositis not improved by day 2/3. Relief from pain on swallowing also
reported
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Kim 1985 (Continued)
Notes No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomised”. No details given.
Allocation concealment? Unclear No information given.
Blinding of participants/carers? Yes Quote: “double blind”.
Blinding of outcome assessors? Yes Quote: “double blind”.
Incomplete outcome data addressed? No Less than half of those randomised were eval-
uated for some outcomes on day 2. No expla-
nation given. 60% lost to follow-up for some
outcomes. drop-outs for mucositis 9%
Free of selective reporting? No Only some of planned outcomes reported for
some of the participants
Free of other bias? Unclear Unclear.
Kostrica 2002
Methods Location: Czech Republic.
Number of centres: One.
Funding source: Not stated.
Recruitment period: March 2000 to March 2001.
Participants Inclusion: Adults over 18 years with head and neck cancer receiving radiation treatment with
minimum dose of 40 Gy, who develop oral mucositis, are on routine supportive treatment
for OM, are likely to return for assessment, have a life expectancy > 6 months, not pregnant,
on contraception (as appropriate). Eligible patients had mucositis in large parts of mouth
Exclusion: Those who have participated in clinical trial in previous 4 weeks, a history of liver
or kidney disease, gastrointestinal ulcers, are ’non-compliant’, intolerant of diclofenac, have
inadequate oral hygiene
77 randomised, 69 included in efficacy analysis by clinician, 66 in efficacy analysis assessment
by patient
Interventions Gr A (n = 39) Diclofenac (free acid 0.074%) mouthwash, 15 ml, three times daily for 2 to 6
weeks
Gr B (n = 38) placebo mouthwash, 15 ml, three times daily for 2 to 6 weeks
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Kostrica 2002 (Continued)
Outcomes Patient assessment for pain - 0 absent; 1 slight; 2 moderate; 3 severe. Dysphagia has 5 point
scale. Assessments for both presented in figures giving mean values for each day from day 0
to 28, and end of treatment. Day 7 used in the analysis
Notes No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “randomised using randomisation
numbers”.
Allocation concealment? Unclear No information reported.
Blinding of participants/carers? Yes Quote: “double blind”.
Blinding of outcome assessors? Yes Quote: “double blind”.
Incomplete outcome data addressed? Yes Post randomisation exclusions clearly de-
scribed for each group.10% lost to follow-up
Free of selective reporting? Yes Planned outcome measure described and re-
ported.
Free of other bias? Unclear No information on funding.
Kuhn 2009
Methods Location: Brazil.
Number of centres: One.
Funding source: Supported by Cancer Institute in Brazil.
Recruitment period: October 2005 to May 2006.
Participants Incusion: Children over 3 years with mixed cancer.
All completed study 9 randomised to laser and 12 to sham.
Interventions low level laser GaAlAs instrument by photon laser II with continuous 830 nm wavelength,
100 mW power versus sham. Treatment time = energy x surface area/power. Energy density
of 4 J/cm2 was delivered to the mucositis lesions. Duration 7 days. Dentist who applied the
laser did not participate in the evaluation
Patients received pain control and symptomatic treatment according to severity of OM
Outcomes OM by a dentist blinded to the intervention. OM was measured 0 to 4 scale (National
Cancer Institute Common Toxicity Criteria version 2 at baseline and every day until complete
healing)
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Kuhn 2009 (Continued)
Notes No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “placebo controlled randomised
trial”.
Quote: “patients were randomised by com-
puter code generation in two groups”
Allocation concealment? Unclear No information.
Blinding of participants/carers? Yes Participants were, carers were not.
Blinding of outcome assessors? Yes Comment: Different to laser provider.
Incomplete outcome data addressed? Yes No drop outs - 0%.
Free of selective reporting? Yes Very clear outcome outcome reporting.
Free of other bias? Yes Comment: Probably.
Loprinzi 1997
Methods Location: USA.
Number of centres: Multicentre (actual number unclear).
Funding source: Grants from the US Public Health Service and the National Cancer Institute
Recruitment period: January to December 1994.
Participants Adults with mixed cancer receiving first cycle 5FU based chemotherapy. Patients who com-
plained of mouth or throat pain were eligible
135 eligible, 50 enrolled, 50 completed.
Interventions Placebo versus sucralfate solution 1 g/30 ml. Rinse 4 times/day for median of 7 days
Outcomes Daily patient reported maximum over 7 days (0 to 4 scale). Clinical evaluation of mucositis by
healthcare provider (“in a manner commonly used in cancer trials usually judged by historical
means”) 4/5 weeks after chemotherapy on WHO 0 to 4 scale. Mucositis not resolved used
Notes All patients had ice chips during chemotherapy.
Power calculation reported: Anticipated that 50% of those recruited would report stomatitis.
Actual % less, (38%) so accrual continued till 50 patients reported stomatitis providing a 73%
power to detect a 1-grade decrease in stomatitis, 85% power to detect a 1.5-grade decrease &
95% power to detect a 2-grade decrease, via a one-sided Wilcoxon test with a 2.5% error rate
Risk of bias
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Loprinzi 1997 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were stratified and ran-
domised....”
Allocation concealment? Unclear No details given.
Blinding of participants/carers? Yes Quote: “Double blind”.
Blinding of outcome assessors? Yes Quote: “Double blind”.
Incomplete outcome data addressed? Yes 131 patients randomised but only 50/131 de-
veloped stomatitis and underwent therapy.
However all randomised patients who devel-
oped stomatitis included in analysis. None
lost to follow-up 0%
Free of selective reporting? Yes Planned outcomes described and reported.
Free of other bias? Unclear Unclear.
Mackie 1991
Methods Location: Seattle, USA.
Number of centres: One.
Funding source: Grants from National Cancer Institute (CA38552), National Institute on
Drug Abuse (DA 05513) and Abbott Laboratories who supplied the PCA pumps
Recruitment period: Not stated.
Randomised not blind. Eligible patients had severe oral mucositis pain. Unclear information
on withdrawals. 10% lost to follow-up
Participants Inclusion: Adolescents aged 12 to 18 years who were presenting for bone marrow transplant
for treatment of leukaemia or lymphoma
35 randomised, 20 completed.
Interventions Gr A PCA 15 µg/kg morphine & 10 min lockout. At night patients had continuous infusion
at rate equal to previous 16 hour mean hourly rate to facilitate sleep
Gr B CI 15 µg/kg morphine after a loading bolus dose of 45 µg/kg. Any increase in rate was
accompanied by a bolus of 3 times the rate change in µg/hr
Outcomes Average pain VAS score (0 to 100) for days 0 to 18, day 7 taken. Mean opiate use mg/kg/hour
for day 7, converted to mg/hr assuming mean weight given in Table 1. The mean duration of
morphine (days) - we are assuming that standard errors not standard deviations are presented
here
Notes No power calculation reported.
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Mackie 1991 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ’randomised’ - no details given.
Allocation concealment? Unclear Nno information given.
Blinding of participants/carers? No Interventions given differently.
Blinding of outcome assessors? No Self assessment.
Incomplete outcome data addressed? Unclear 10/15 patients who required less than 7 days
treatment are accounted for and their allo-
cated treatment given. However 43% of ran-
domised patients are not included in the out-
come assessment which may cause a bias
Free of selective reporting? Yes Yes.
Free of other bias? No Comment: Patients who experienced adverse
events such as nausea were excluded
Malik 1997
Methods Location: Pakistan.
Number of centres: One.
Funding source: Brooks Pharmaceutical co supplied the TCDO and placebo
Recruitment period: Not stated.
Randomised, double blind. Eligible patients had mucositis on entry. None lost to follow-up
Participants Adults with mixed cancer, with oral mucositis WHO grades 2 to 4, induced by chemotherapy
in preceding 2 weeks, including those given prophylactic nystatin or antiseptic mouthwash
62 eligible, 62 randomised , 62 completed.
Interventions GrA (n = 32)TCDO (tetrachlorodecaoxide). 10ml twice daily, swish then swallow.Maximum
7 days
GrB (n = 30) placebo 10 ml twice daily, swish then swallow. Maximum 7 days
Outcomes Objective clinical mucositis improvement by day 3 using WHO criteria on 0 to 4 scale,
mucositis not improved by day 3 used. Symptomatic improvement by patient of oral pain
and ability to eat by day 3
Notes No power calculation reported.
Risk of bias
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Malik 1997 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “double blind placebo controlled ran-
domised trial”.
Allocation concealment? Unclear No information.
Blinding of participants/carers? Yes Quote: “Double blind”.
Comment: TCDO and placebo supplied in
identical containers.
Blinding of outcome assessors? Yes Quote: “Double blind”.
Incomplete outcome data addressed? Yes All randomised patients included in analysis.
Free of selective reporting? Yes Planned outcomes described and reported.
Free of other bias? Unclear Comment: Some pharmaceutical funding.
Masucci 2005
Methods Location: Sweden.
Number of centres: Five.
Funding source: Unrestricted grant from Schering Plough AB, Stockholm
Duration: End of radiotherapy.
Participants Adults with recently detected head and neck cancer, who were about to undergo radiotherapy.
92 patients were entered onto database and randomised. Only 62 developed mucositis scores
> 1.5. 61 included an end point. 10 patients had only 1 evaluation. 51 analysed for mucositis
outcome
Interventions GrA: Recombinant human granulocyte monocyte-colony stimulating factor GM-CSF (Mol-
gramostim, Leucomax, Schering-Plough, Sweden) 4 g/kg/d sc. By injection every day (in-
cluding radiotherapy free days) from when oral mucositis scored reached 1.5 until full radio-
therapy dose was given. ’Conventional care’ as well
GrB: ’Conventional care’ - details not provided.
Outcomes Improvement in mucositis scores assessed as change of 1 unit from baseline (this was a mean
value over several sites). Assessment at 1, 2 and end of radiotherapy. Additional side effects:
nutritional status, weight loss. Pain and difficulty eating were assessed but data not presented
(pain and difficulty eating incorporated in mucositis scores)
Notes Power calculation “Assuming a binomial distribution 2x39 patients were needed to achieve
a power of 80%, or 2 x 52 for a power of 90%, to reject the hypothesis of equal success
probabilities, using a 2 sided test at the significance level of 5% (normal approximation)”
Risk of bias
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Masucci 2005 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation performed centrally at start of
radiotherapy ’according to a computer gener-
ated code in blocks of 10.’ Only those who
subsequently developed OM score greater
than 1.5 entered the study
Allocation concealment? Yes ’Treatment allocation at centres performedus-
ing sealed envelopes’
Blinding of participants/carers? No Quote: “multicentre open randomised phase
III study”.
Blinding of outcome assessors? Yes Outcome assessment conducted by a physi-
cian or dentist blinded to treatment allocation
Incomplete outcome data addressed? Yes Comment: Randomised patients accounted
for: 21/92 (11 and 10 in GrA & Gr B respec-
tively) patients did not enter treatment be-
cause they did not develop OM score > 1.5.
A further 5 patients in each group excluded
from analysis due to insufficient documen-
tation, leaving 61/71 evaluable patients. 51
patients included in primary outcome. 28%
drop-outs (based on those who were eligible)
3 and 7 patients from GM-CSF & control
groups respectively did not have data for pri-
mary endpoint (after 2 weeks)
Free of selective reporting? Yes Planned outcomes reported.
Free of other bias? Unclear Unclear.
Papila 2003
Methods Location: Turkey.
Number of centres: One.
Funding source: Not stated.
Recruitment period: Not stated.
Participants Adults with solid cancer (head, neck, lung) receiving chemotherapy, with oral mucositis. 40
patients eligible, enrolled and completed
Interventions GM-CSF 400 µg in 100 ml saline 4x daily versus nystatin 1 ml 4x daily
Outcomes Mean time to heal (days) and standard deviations are given.
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Papila 2003 (Continued)
Notes No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: ’randomly assigned’ - no further in-
formation given.
Allocation concealment? Unclear No information given.
Blinding of participants/carers? No Not mentioned.
Blinding of outcome assessors? No Not mentioned.
Incomplete outcome data addressed? Yes All randomised patients included in outcome
assessment, 0% drop-out
Free of selective reporting? Yes Planned outcomes reported.
Free of other bias? Unclear Unclear.
Pillitteri 1998
Methods Location: Liverpoool, United Kingdom.
Number of centres: One.
Funding source: Not stated.
Recruitment period: February 1995 to August 1997.
Participants Inclusion: Patients undergoing conditioning chemotherapy in preparation for bone marrow
transplant or autologous transplant of peripheral blood stem cells (cyclophosphamide/TBI,
high dose melphalan or BEAM)
81 screened, 65 randomised, 43 sought treatment for severe mucositis pain when non-opioids
were ineffective, 35 completed
Interventions GrA (n = 33) Diamorphine by PCA 0.8 mg bolus + 2 mg/hour (max) to max of 96 mg/24
hour for 14 days
GrB (n = 32) Diamorphine by continuous infusion, 24 mg in 24 hour (with requested doses
increases up to a max dose of 96 mg/24 hour) for up to 14 days
Outcomes Average pain VAS score (0 to 100) day 7 taken. Mean opiate use mg per hour for day 7.
The mean duration of morphine (days) - we have converted the standard errors to standard
deviations
Notes All patients, on 2 occasions, received prophylactic amphotericin lozenges, nystatin, chlorhex-
idine, oral acyclovir, oral ciprofloxacin and colistin. No power calculation reported
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Pillitteri 1998 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Quote: “serial sealed envelopes containing
computer generated random treatment allo-
cation”
Allocation concealment? Yes Quote: “serial sealed envelopes containing
computer generated random treatment allo-
cation”
Blinding of participants/carers? No Interventions given differently.
Blinding of outcome assessors? No Self assessment.
Incomplete outcome data addressed? Yes Comment: only 45/65 (66%) of those ran-
domised required treatment for mucositis. 8
patients who received treatment were subse-
quently excluded from analysis (4 in Gr A
failed attempt at PCA and 1 needed diamor-
phine for ’other pain’, and 3 in Gr B needed
diamorphine for ’other pain’). 18% drop-outs
Free of selective reporting? Yes Planned outcomes described and reported.
Free of other bias? Unclear Not all randomised participants required opi-




Number of centres: One.
Funding source: Not stated.
Recruitment period: Not stated.
Participants Inclusion: Adults with advanced malignancies (mostly gastrointestinal) treated with 5FU and
folinic acid or fluorouracil. Eligible patients had oral mucositis grade 2 or 3
44 enrolled, 44 completed.
Interventions Gr A (n = 22) Allopurinol dispersion mouthwash 300 mg dissolved in water, rinse for 1 min
4 to 6 times/day for at least 7 days
GrB (n = 22) Placebo mouthwash, rinse for 1 min 4 to 6 times/day for at least 7 days
Outcomes Clinical evaluation of mucositis resolved, or improved at 5 days using WHO criteria (0 to 4
scale), by physician. Mean duration of mucositis (days used)
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Porta 1994 (Continued)
Notes No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “patients were randomised to received
in a double blind manner”
Allocation concealment? Unclear No information given.
Blinding of participants/carers? Yes Double blind.
Blinding of outcome assessors? Yes Double blind.
Incomplete outcome data addressed? Yes All randomised patients included in outcome
assessments.
Free of selective reporting? Unclear 5 day treatment cycle unclear.
Free of other bias? Unclear Funding unclear.
Schedler 1994
Methods Location: Germany.
Number of centres: One.
Funding source: Unclear.
Recruitment period: Unclear.
Participants Inclusion: Adults with Grade 1 or 2 mucositis after undergoing radiotherapy for head and
neck cancer who had Karnofsky Performance Status > 50%
Exclusion: Previous radiotherapy, pervious therapy for oral mucositis, recent chemotherapy,
skin or mucosal defects
Interventions Gr B (n = 39) Polyvalent immunoglobulin (160 mg/ml) 10 ml IM on day ), then 5 ml on
days 2 & 4
Gr B (n = 42) Placebo (10% human albumin) 10 ml IM on day ), then 5 ml on days 2 & 4
Outcomes EORTC grade did not reduce to 0 or 1 used in review.
Notes Double blind study up to day 7. Both groups received nystatin. Power calculation - not
described
Risk of bias
Item Authors’ judgement Description
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Schedler 1994 (Continued)
Adequate sequence generation? Unclear Quote: “A randomised double blind study”.
Allocation concealment? Unclear No information given.
Blinding of participants/carers? Yes Double blind.
Blinding of outcome assessors? Yes Double blind.
Incomplete outcome data addressed? Yes Only one dropout from placebo group due to
poor general health 1% drop out
Free of selective reporting? Unclear Unclear.
Free of other bias? Unclear Unclear funding.
Schubert 1987
Methods Location: USA.
Number of centres: Multicentre.
Funding source: Inter America Pharmaceuticals.
Recruitment period: Not stated.
Participants Inclusion: Adultswithmoderate oralmucositis pain after chemotherapy of chemoradiotherapy
with clinically obvious mucosal changes consistent with oral mucositis
Exclusion: Patients taking systemic analgesics or anti-inflammatory drugs or those using
topical anaesthetics
44 randomised, 44 completed.
Interventions Gr A (n = 25): Benzydamine 0.15% in mouthwash base. Swish and hold 15 ml of solution
for 1 min every 2 hours. Minimum of 5 doses per day
Gr B (n = 19): Placebo. Swish and hold 15 ml of solution for 1 min every 2 hours. Minimum
of 5 doses per day
Study length min 9 hours, max 10 days.
Outcomes Patients assessment of pain relief at day 1.We dichotomised this as poor versus fair to excellent
and used this as an outcome for whether mucositis had improved or not
Notes Sample size calculation reported (post hoc): to have a 90% chance of detecting a significant
difference between placebo and benzydamine solutions (assuming placebo 45% effective and
benzydamine 65%) would require 105 subjects per arm, if difference in effectiveness between
the groups is increased to 25% (45% and 70%) then would need 75 subjects per group. Study
planned to accrue 214 subjects
Risk of bias
Item Authors’ judgement Description
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Schubert 1987 (Continued)
Adequate sequence generation? Unclear Quote: ’A multicentre double blind con-
trolled trial was undertaken”
Allocation concealment? Unclear No information given.
Blinding of participants/carers? Yes Double blind.
Blinding of outcome assessors? Yes Double blind.
Incomplete outcome data addressed? Yes All randomised patients included in outcome
assessment.
Free of selective reporting? No Preliminary results reported, for pain at day 1
and duration of treatment
Free of other bias? Unclear Unclear.
Syrjala 1992
Methods Location: USA.
Number of centres: One.
Funding source: Grants fromNational Cancer Institute (CA 38522) AmericanCancer Society
(Institutional grant IN-24), Biomedical Research Support Grant (RR-05346)
Recruitment period: Not stated.
Randomised patients and assessor not blinded.
Participants Inclusion: Adults with haematological malignancy or lymphoma having BMT, who spoke
English and were aged > 18 years. Patients had oral mucositis with pain
67 enrolled, 45 completed.
Interventions Gr A (n = 18) HYP Hypnosis - 2 training sessions prior to treatment twice weekly sessions
for 5 weeks
Gr B (n = 17) CB Cognitive Behavioural coping skills,cognitive restructuring, & relaxation
- 2 training sessions prior to treatment twice weekly sessions for 5 weeks
Gr C (n = 16) TCC Therapist contact control group - therapist met with patients for a chat
but no new coping skills were taught - 2 training sessions prior to treatment twice weekly
sessions for 5 weeks
Gr D (n = 16) TAU Treatment as usual group - received ’standard interventions for nausea,
pain and emesis
Outcomes Average pain VAS score mean over week 3. Average mean opiate use per day for week 3
Notes Average mean opiate use per day was converted to hourly rate by dividing by 24. No power
calculation reported
Risk of bias
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Syrjala 1992 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were randomised to one of
4 intervention groups”
Allocation concealment? Unclear No information given.
Blinding of participants/carers? No Interventions delivered differently.
Blinding of outcome assessors? No Self assessment.
Incomplete outcome data addressed? Yes Reasons for post randomisation withdrawal
and exclusions given for each group and bal-
anced across groups. (17 patients too ill to
continue &5 hadmissing data (HYP 6, CB 6,
TCC 4, TAU 6 respectively). 33% withdrew
Free of selective reporting? Yes planned outcomes described and reported.
Free of other bias? Unclear Quote: “During random assignment a
marked sex difference occurred between
groups”
Syrjala 1995
Methods Location: Seattle USA.
Number of centres: One.
Funding source: NCI Grants (38552 & 57807).
Recruitment period: Not stated.
Participants Inclusion: English speaking adults undergoing bone marrow transplant, aged > 18 years, with
leukaemia, myelodysplasia or lymphoma. Had to receive 2 outpatient training sessions and
remain well enough to participate for 1 month after their bone marrow transplant
Exclusion: Those actively practising imagery.
161 randomised, 94 completed.
Interventions Gr A: R&I relaxation & imagery training.
Gr B: CB cognitive /behavioural coping skills training.
Gr C: TS therapist support.
Gr D: TAU treatment as usual (no training).
2 training sessions prior to treatment, then twice weekly sessions for 5 weeks
All patients received standard interventions for pain, nausea and emesis
Outcomes Average pain VAS score mean day 6 to 26.
Notes No power calculation reported.
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Syrjala 1995 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Randomised patients to one of four
intervention conditions. Randomisation was
stratified for conditioning regimen (CT),
whether patients had total body irradiation,
and gender”
Allocation concealment? Unclear No information given.
Blinding of participants/carers? Yes Quote: “Patients blinded to content of other
intervention groups. They were told the con-
tent only for the intervention they received”
Blinding of outcome assessors? Yes Quote: “These research assistants were blind
to the randomisation of the patients”
Incomplete outcome data addressed? Unclear 67/161 = 42% did not complete the study.
Details reasons given in Table 2 and reasons
and numbers similar in each group. However
authors acknowledge that this introduces a
risk of bias and have attempted to deal with
this in the analysis
Free of selective reporting? Yes Planned outcomes described and reported.
Free of other bias? Unclear Baseline characteristics not given by allocated
treatment group - uncertainty as to whether
randomisation resulted in balanced groups
and/or high proportion of non completers
caused bias
Valcarcel 2000
Methods Location: Barcelona, Spain.
Number of centres: One.
Funding source: rhGM-CSF (Molgramastin) supplied by Schering Plough
Recruitment period: October 1998 to March 2001.
Participants Inclusion: AdultswithWHOgrade 3 to 4oralmucositiswhohadhaematologicalmalignancies
undergoing stem cell transplantation
41 patients recruited, 35 completed.
Interventions GrA (n = 18) rhGM-CSF 400 ug of rhGM-CSF dissolved in 200 ml saline solution,
mouthrinse to be used for 30 mins, three times daily, for 5 days. Swish and spit
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Valcarcel 2000 (Continued)
GrB (n = 23) placebo (saline solution only), mouthrinse to be used for 30 mins, three times
daily, for 5 days. Swish and spit
Outcomes Overall duration of mucositis (days) is used. Reduction in at least 1 grade of mucositis, need
for PCAmorphine (however there were significantly more already needing this in the placebo
group at the beginning of the treatment protocol)
Notes No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Double blind randomised controlled
trial”.
Quote: “Both patient randomisation and
drug prepartion were performed in the phar-
macy department”
Allocation concealment? Unclear No further details given.
Blinding of participants/carers? Yes Double blind.
Quote: “Active and placebo mouthrinses
looked and tasted identical”
Blinding of outcome assessors? Yes Double blind.
Incomplete outcome data addressed? Unclear 6/41 (15%) excluded post randomisation,
reasons (3 died, 2 refused, 1 required ventila-
tion). 16/18 inGrA&19/23Gr B completed
treatment SF
Free of selective reporting? Yes Planned outcomes described and reported.
Free of other bias? Unclear Unclear.
Wadleigh 1992
Methods Location: USA.
Number of centres: One.
Funding source: Not stated.
Recruitment period: Not stated.
Participants Inclusion: Adult cancer patients who had undergone chemotherapy with no prior treatment
for oral mucositis, no oral yeast infection or oral herpes infection. All had oral mucositis
grades 2 to 4 (WHO criteria)
“24 were initially evaluated but 6 were subsequently excluded”. Unclear when randomisation
took place
54Interventions for treating oral mucositis for patients with cancer receiving treatment (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wadleigh 1992 (Continued)
Interventions Gr A (n = 9) Vitamin E oil 400 mg/ml 1 ml applied topically to lesions twice daily for 5 days
Gr B (n = 9) Placebo (coconut and soyabean oil) 1 ml applied topically to lesions twice daily
for 5 days
Outcomes Clinical evaluation of eradication of lesions over 5 day study period using WHO criteria (0
to 4 scale)
Notes No power calculation reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Randomised double-blind placebo
controlled study. Patients were randomly as-
signed to receive in a double blind manner
vitamin E or placebo”
Allocation concealment? Unclear No details given.
Blinding of participants/carers? Yes Double blind.
Blinding of outcome assessors? Yes Ddouble blind.
Incomplete outcome data addressed? Unclear Unclear information on withdrawals which
were either before or after randomisation. 0%
or 25% lost to follow-up
Free of selective reporting? Yes Planned outcome described and reported.
Free of other bias? Yes Yes.
Zucker 1998
Methods Location: Germany.
Number of centres: One.
Funding source: Ute Huneke-Stiftung & Leukamie Liga e.V.
Recruitment period: August 1994 to February 1996.
Participants Inclusions: Adults with a haematological neoplasia or malignant lymphoma scheduled for
bone marrow transplantation. Eligible patients had mucositis pain. 20 patients were ran-
domised
Exclusion: those who refused consent, failed to understand the protocol for pain therapy and
measurement, who had prior chronic or recurrent opioid medication, those with a history of
alcohol or drug abuse
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Zucker 1998 (Continued)
Interventions Gr A (n = 10) Staff controlled pethidine infusion (100 mg pethidine continuously on first
day, 200 mg on second and 300 mg on third. From day 4 this was increased up to 400 mg.
Supplemental bolus doses of 25 mg pethidine were administered through BMT staff “when
needed”
Gr B (n = 10) Patient controlled pethidine (PCA device delivering 150 mg pethidine/day
continuously and 25 mg per demand dose. The lockout time was 45 min and speed of
injection of a single bolus dose to 600 mg/h)
Outcomes Patient VAS pain scale. 6 times per day. Pethidine consumption was also monitored (mg/day
shown in figure). Patient mean pain scores were also recorded
Notes All patients also received ondansetron via continuous infusion. No power calculation reported
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Randomised assignment”.
Allocation concealment? Unclear No information given.
Blinding of participants/carers? No PCA versus staff controlled analgesia.
Blinding of outcome assessors? No Pain assessed by patient.
Incomplete outcome data addressed? Yes One patient from group B excluded from
analysis. No reason given but unlikely to af-
fect results. Drop out 5%
Free of selective reporting? Yes Pplanned outcomes described and reported.
Free of other bias? Yes Yes.
BMT = bone marrow transplantation
TBI = total body irradiation
VAS = visual analogue scale
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Agüeros 2004 Abstract, insufficient information (I).
Allison 1995 Not RCT (sucralfate plus fluconazole).
Atkins 2004 Abstract, insufficient information.
Awada 2004 Not RCT and mucositis not primary outcome.
Barker 1991 No useable data, only medians given (sucralfate versus diphenhydramine syrup/kaolin-pectin)
Beltran 1990 Abstract, insufficient information (bencidamide mouthwash versus placebo)
Biswal 2002 Abstract, insufficient information (PCA versus CI).
Biswal 2003 Prevention not treatment of mucositis (honey).
Bondi 1997 No useable data, outcome looks at progression of mucositis (tobramycin polymyxin E amphotericin versus
diphenhydramine)
Carnel 1990 No useable data, unclear how many patients in each group (lidocaine 1% cocaine versus dyclonine hy-
drochloride versus diphenhydramine kaolin-pectin versus placebo)
Cerchietti 2002 No relevant outcomes (morphine mouthwash versus ’magic’ mouthwash)
Cerchietti 2003 Problems with design and no mucositis outcomes in form which can be used in the review
Chambers 2006 Abstract, insufficient information (RK-0102 oral rinse).
Chapman 1997 No useable data, severity scores given (morphine versus hydromorphone)
Cheng 2004 Prevention of mucositis not treatment.
Collins 1996 No relevant outcomes (morphine versus hydromorphone).
Collova 2004 Abstract, insufficient information.
Connor 1996 Abstract, insufficient information (PCA versus CI).
Crawford 1994 Abstract, insufficient information.
Domenge 1999 Abstract, insufficient information (fluconazole versus amphotericin B)
Ehrnrooth 1999 Abstract, insufficient information (morphine versus tricyclic antidepressant)
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(Continued)
Eren 2007 Study published in turkish language with English abstract. Unit of randomisation is chemotherapy cycles
not patients (rGM - CSF versus standard care comprising chlorhexidine + sodium bicarbonate + Vitamin
E + mycostatin + ranitidine)
Evans 1998 Abstract, insufficient information (GM-CSF versus placebo).
Evensen 2001 Prevention not treatment of mucositis (Na-sucrose octasulfate versus placebo)
Ferretti 1987 Abstract, insufficient information (chlorhexidine versus placebo)
Foote 1996 Abstract, insufficient information (antibiotic lozenge-tobramycin, polymyxin, amphotericin B versus
placebo)
Giles 2002 Abstract, insufficient information.
Giles 2004 Prevention of mucositis not treatment.
Girdler 1995 No useable data, number of ulcers and area covered, means but no SDs (epidermal growth factor versus
placebo)
Gobetti 1999 Abstract, insufficient information.
Haritha 2009 Abstract, insufficient information (oral morphine).
Hejna 2000 Abstract, insufficient information (GM-CSF mouthwashes).
Kin-Fong Cheng 2006 Not eligible as excluded patients with severe (> 2) oral mucositis.
Kostler 2005 Not RCT.
Labbate 2003 Not RCT (contacted authors to check but no reply to e-mail 10/8/06)
Lever 1987 Study halted early - protocol violation (benzydamine versus HSC mouthwashes)
Lilleby 2006 Prevention of mucositis not treatment.
Lockhart 2005 Prevention of mucositis not treatment.
Mantovani 2003 Not RCT (GM-CFS).
Marinoni 1996 Abstract, insufficient information (many interventions).
Meredith 1997 Design only treats when mucositis present but the results include patients not treated (sucralphate versus
placebo)
Mitrokhin 2003 Translated from Russian. Not RCT.
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(Continued)
Naidu 2005 Data presented within groups (comparing change from baseline) only no comparison between groups (Oral
polyherb)
Oguchi 1998 Not RCT (polymer film).
Oshitani 1990 Not RCT (sodium alginate versus no treatment control).
Papila 1999 Unclear if RCT - no reply to letter or e-mail (sucralfate versus placebo)
Pession 1997 Abstract, insufficient information.
Pouli 1999 Abstract, insufficient information.
Rades 2004 Prevention of mucositis not treatment.
Radmard 2002 Abstract, insufficient information.
Rothwell 1990 No useable data, results presented as means (rinse-hydrocortisone, nystatin, tetracyclin, diphenhydramine
versus placebo)
Schmid 2006 No oral outcome and wrong intervention for mucositis.
Schwerkkoske 1999 Abstract, insufficient information.
Shaiova 2004 No appropriate outcomes and unsure of design.
She 2000 Unclear if RCT and insufficient information.
Shen 2004 Unclear if RCT and insufficient information.
Sprinzl 2001 Trial designed so that allocated patients received intervention on onset of mucositis, however outcomes
measured at time from beginning of study. Patients had been on intervention for different times. We felt
we could not use the data (GM-CSF versus hydrocortisone mouthwash)
Stokman 2004 Not RCT.
Su 2004 Abstract, insufficient information.
Svanberg 2004 Abstract, insufficient information.
Teshima 1986 Insufficient information on trial to include and no response to letter (sent in Japanese)
Valcarcel 2002 Abstract, insufficient information.
Vayne-Bossert 2010 Cross-over study with carry-over effect from first to second period. Only 9 patient in cross-over, too few to
undertake first period analysis
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(Continued)
Vela-Ojeda 1996 Abstract, insufficient information.
CI = continuous infusion
GM-CSF = granulocyte macrophage-colony stimulating factor
PCA = patient controlled analgesia
RCT = randomised controlled trial
SD = standard deviation
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D A T A A N D A N A L Y S E S
Comparison 1. benzydamine mouthwash versus placebo




participants Statistical method Effect size
1 Improvement in mucositis 2 102 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.94, 1.60]
Comparison 2. low level laser versus sham




participants Statistical method Effect size
1 Mild to moderate mucositis 2 57 Risk Ratio (M-H, Fixed, 95% CI) 5.28 [2.30, 12.13]
Comparison 3. sucralfate versus placebo/salt and water/salt and soda




participants Statistical method Effect size
1 Mucostis eradicated 2 84 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.66, 1.94]
Comparison 4. morphine (PCA) versus morphine (CI)




participants Statistical method Effect size
1 Average pain score 3 113 Mean Difference (IV, Fixed, 95% CI) -2.49 [-12.28, 7.29]
2 Daily mean opiate intake per
hour
3 113 Mean Difference (IV, Fixed, 95% CI) -0.65 [-1.20, -0.09]
3 Duration of pain control 3 113 Mean Difference (IV, Fixed, 95% CI) -1.87 [-3.49, -0.25]
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Comparison 5. therapist versus control




participants Statistical method Effect size
1 Average pain score 2 69 Mean Difference (IV, Fixed, 95% CI) -5.61 [-17.25, 6.02]
Comparison 6. cognitive behaviour versus control




participants Statistical method Effect size
1 Average pain score 2 68 Mean Difference (IV, Fixed, 95% CI) -7.29 [-17.40, 2.83]
Analysis 1.1. Comparison 1 benzydamine mouthwash versus placebo, Outcome 1 Improvement in
mucositis.
Review: Interventions for treating oral mucositis for patients with cancer receiving treatment
Comparison: 1 benzydamine mouthwash versus placebo
Outcome: 1 Improvement in mucositis
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kim 1985 14/31 6/27 23.9 % 2.03 [ 0.91, 4.55 ]
Schubert 1987 23/25 18/19 76.1 % 0.97 [ 0.83, 1.14 ]
Total (95% CI) 56 46 100.0 % 1.22 [ 0.94, 1.60 ]
Total events: 37 (Experimental), 24 (Control)
Heterogeneity: Chi2 = 9.91, df = 1 (P = 0.002); I2 =90%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours placebo Favours benzydamine
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Analysis 2.1. Comparison 2 low level laser versus sham, Outcome 1 Mild to moderate mucositis.
Review: Interventions for treating oral mucositis for patients with cancer receiving treatment
Comparison: 2 low level laser versus sham
Outcome: 1 Mild to moderate mucositis
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Genot-Klastersky 2008 15/18 2/18 43.8 % 7.50 [ 2.00, 28.16 ]
Kuhn 2009 8/9 3/12 56.3 % 3.56 [ 1.30, 9.73 ]
Total (95% CI) 27 30 100.0 % 5.28 [ 2.30, 12.13 ]
Total events: 23 (Experimental), 5 (Control)
Heterogeneity: Chi2 = 0.86, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 3.92 (P = 0.000088)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours sham Favours laser
Analysis 3.1. Comparison 3 sucralfate versus placebo/salt and water/salt and soda, Outcome 1 Mucostis
eradicated.
Review: Interventions for treating oral mucositis for patients with cancer receiving treatment
Comparison: 3 sucralfate versus placebo/salt and water/salt and soda
Outcome: 1 Mucostis eradicated
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chiara 2001 11/17 10/17 82.2 % 1.10 [ 0.65, 1.87 ]
Loprinzi 1997 3/27 2/23 17.8 % 1.28 [ 0.23, 7.00 ]
Total (95% CI) 44 40 100.0 % 1.13 [ 0.66, 1.94 ]
Total events: 14 (Experimental), 12 (Control)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
0.05 0.2 1 5 20
Favours placebo Favours sucralfate
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Analysis 4.1. Comparison 4 morphine (PCA) versus morphine (CI), Outcome 1 Average pain score.
Review: Interventions for treating oral mucositis for patients with cancer receiving treatment
Comparison: 4 morphine (PCA) versus morphine (CI)
Outcome: 1 Average pain score





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hill 1990 26 52 (23.8) 32 50 (25.6) 58.9 % 2.00 [ -10.74, 14.74 ]
Mackie 1991 10 53 (24) 10 61 (24) 21.6 % -8.00 [ -29.04, 13.04 ]
Pillitteri 1998 18 10 (34) 17 20 (33) 19.4 % -10.00 [ -32.20, 12.20 ]
Total (95% CI) 54 59 100.0 % -2.49 [ -12.28, 7.29 ]
Heterogeneity: Chi2 = 1.18, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours morphine PCA Favours morphine CI
Analysis 4.2. Comparison 4 morphine (PCA) versus morphine (CI), Outcome 2 Daily mean opiate intake
per hour.
Review: Interventions for treating oral mucositis for patients with cancer receiving treatment
Comparison: 4 morphine (PCA) versus morphine (CI)
Outcome: 2 Daily mean opiate intake per hour





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hill 1990 26 2.4 (3.3) 32 4 (4.4) 7.9 % -1.60 [ -3.58, 0.38 ]
Mackie 1991 10 2.2 (3.3) 10 3.9 (2.3) 5.0 % -1.70 [ -4.19, 0.79 ]
Pillitteri 1998 18 0.8 (0.9) 17 1.3 (0.9) 87.1 % -0.50 [ -1.10, 0.10 ]
Total (95% CI) 54 59 100.0 % -0.65 [ -1.20, -0.09 ]
Heterogeneity: Chi2 = 1.81, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours morphine PCA Favours morphine CI
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Analysis 4.3. Comparison 4 morphine (PCA) versus morphine (CI), Outcome 3 Duration of pain control.
Review: Interventions for treating oral mucositis for patients with cancer receiving treatment
Comparison: 4 morphine (PCA) versus morphine (CI)
Outcome: 3 Duration of pain control





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hill 1990 26 15.1 (9.7) 32 16.8 (10.8) 9.5 % -1.70 [ -6.98, 3.58 ]
Mackie 1991 10 14.3 (6) 10 16.6 (5.1) 11.1 % -2.30 [ -7.18, 2.58 ]
Pillitteri 1998 18 7.17 (2.8) 17 9 (2.7) 79.5 % -1.83 [ -3.65, -0.01 ]
Total (95% CI) 54 59 100.0 % -1.87 [ -3.49, -0.25 ]
Heterogeneity: Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours morphine PCA Favours morphine CI
Analysis 5.1. Comparison 5 therapist versus control, Outcome 1 Average pain score.
Review: Interventions for treating oral mucositis for patients with cancer receiving treatment
Comparison: 5 therapist versus control
Outcome: 1 Average pain score





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Syrjala 1992 12 37.9 (24) 10 33.5 (29.9) 25.7 % 4.40 [ -18.57, 27.37 ]
Syrjala 1995 24 44.71 (23.95) 23 53.78 (23.25) 74.3 % -9.07 [ -22.56, 4.42 ]
Total (95% CI) 36 33 100.0 % -5.61 [ -17.25, 6.02 ]
Heterogeneity: Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours therapist Favours control
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Analysis 6.1. Comparison 6 cognitive behaviour versus control, Outcome 1 Average pain score.
Review: Interventions for treating oral mucositis for patients with cancer receiving treatment
Comparison: 6 cognitive behaviour versus control
Outcome: 1 Average pain score





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Syrjala 1992 11 28.9 (13.9) 10 33.5 (29.9) 24.9 % -4.60 [ -24.87, 15.67 ]
Syrjala 1995 24 45.6 (16.95) 23 53.78 (23.25) 75.1 % -8.18 [ -19.85, 3.49 ]
Total (95% CI) 35 33 100.0 % -7.29 [ -17.40, 2.83 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours cognitive behave Favours control
A D D I T I O N A L T A B L E S
Table 1. Data from comparisons and outcomes with single trials












19 22 3 22 RR6.33 (2.18, 18.37) 0.0007
Mucositis
eradicated















51 67 49 71 RR 1.10 (0.90, 1.35) 0.35
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36 60 8 60 RR 4.50 [2.29, 8.86] < 0.001
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1.5 (2.4) 6 3.2 (1.2) 6 MD -1.70 [-3.85, 0.
45]
0.12









































29 32 22 30 RR 1.24 [0.97, 1.58] 0.09
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33.5 (17.7) 20 52.6 (20.1) 19 MD -19.10 [-31.01, -
7.19]
0.002
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23.0 (31.1) 12 33.5 (29.9) 10 MD -10.50 [-36.05,
15.05]
0.42
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1.21 (3.78) 12 1.66 (5.4) 10 MD -0.45 [-4.42, 3.
52]
0.82
A P P E N D I C E S
Appendix 1. Cochrane Oral Health Group’s Trials Register; Cochrane Pain, Palliative & Supportive
Care Group’s Trials Register search strategy
((neoplasm* OR leukemia OR leukaemia OR leukaemia OR lymphoma* OR plasmacytoma OR “histiocytosis malignant” OR retic-
uloendotheliosis OR “sarcoma mast cell” OR “Letterer Siwe disease” OR “immunoproliferative small intestine disease” OR “Hodgkin
disease” OR “histiocytosis malignant” OR “bone marrow transplant*” OR cancer* Or tumor* OR tumour* OR malignan* OR neu-
tropeni* OR carcino* OR adenocarcinoma* OR radioth* OR radiat* OR radiochemo* OR irradiat* OR chemo*) AND (stomatitis
OR “Stevens Johnson syndrome” OR “candidiasis oral” OR mucositis OR (oral AND (cand* OR mucos* OR fung*)) OR mycosis
OR mycotic OR thrush))
Appendix 2. The Cochrane Central Register of Controlled Clinical Trials (CENTRAL) search
strategy





5. Exp BONE MARROW TRANSPLANTATION
6. neoplasm* or cancer* or carcino* or malignan*
7. leukemi* or leukaemia*




12. (radioth* or radiat* or irradiat* or radiochemo*)
13. (bone next marrow next transplant*)
14. chemo* or radiochemo*





20. (stevens next johnson next syndrome)
21. mucositis
22. oral near cand*
23. mouth near cand*
24. oral and fung*
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25. mouth and fung*
26. (mycosis or mycotic or thrush)
27. #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26
28. #15 AND #27





5. Bone Marrow Transplantation/
6. neoplasm$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name,
device trade name]
7. cancer$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name,
device trade name]
8. (leukaemi$ or leukemi$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug
manufacturer name, device trade name]
9. (tumour$ or tumor$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manu-
facturer name, device trade name]
10. malignan$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drugmanufacturer name,
device trade name]
11. neutropeni$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer
name, device trade name]
12. carcino$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name,
device trade name]
13. adenocarcinoma$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drugmanufacturer
name, device trade name]
14. lymphoma$.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer
name, device trade name]
15. (radioth$ or radiat$ or irradiat$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer,
drug manufacturer name, device trade name]
16. (bone adj marrow adj5 transplant$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer,
drug manufacturer name, device trade name]





21. stomatitis.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name,
device trade name]
22. mucositis.mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name,
device trade name]
23. (oral and cand$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer
name, device trade name]
24. (oral adj6mucos$).mp. [mp=title, abstract, subject headings, drug trade name, original title, devicemanufacturer, drugmanufacturer
name, device trade name]
25. (oral and fung$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer
name, device trade name]
26. (mycosis or mycotic).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manu-
facturer name, device trade name]
27. or/19-26
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28. 18 and 27
The above subject search was run with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomized trials in
MEDLINE: sensitivity maximising version (September 2009 revision) as referenced in Chapter 6 and detailed in box 6.4.c of The Cochrane
Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009].
1. randomized controlled trial.pt.








10. exp animals/ not humans.sh.
11. 9 not 10





5. exp bone marrow transplantation/
6. (neoplasm$or cancer$ or leukemi$or leukaemi$ or tumour$ or tumor$ ormalignan$ or neutropeni$ or carcino$ or adenocarcinoma$
or lymphoma$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer
name]
7. (radioth$ or radiat$ or irradiat$ or radiochemo$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device
manufacturer, drug manufacturer name]
8. (bone marrow adj3 transplant$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug
manufacturer name]




13. (stomatitis or mucositis or (oral and candid$) or (oral adj4 mucositis) or (oral and fung$) or mycosis or mycotic or thrush).mp.
[mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]
14. or/11-13
15. 10 and 14




3. (crossover$ or cross over$ or cross-over$).ti,ab.
4. placebo$.ti,ab.
5. (doubl$ adj blind$).ti,ab.






12. RANDOMIZED CONTROLLED TRIAL.sh.
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13. SINGLE BLIND PROCEDURE.sh.
14. or/1-13
15. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/
16. HUMAN/
17. 16 and 15
18. 15 not 17
19. 14 not 18





S5 (MH “Bone Marrow Transplantation”)
S6 neoplasm*
S7 cancer*
S8 (leukemi* or leukaemi*)






S15 (radioth* or radiat* or irradiat*)
S16 (bone N1 marrow N5 transplant*)
S17 chemo*
S18 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or
S12 or S13 or S14 or S15 or S16 or S17
S19 MH “Stomatitis+”
S20 MH “Candidiasis, Oral”
S21 stomatitis
S22 mucositis
S23 (oral and cand*)
S24 (oral N6 mucos*)
S25 (oral and fung*)
S26 (mycosis or mycotic)
S27 S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26
S28 S18 AND S27
The above subject search was run with the Cochrane Oral Health Group sensitive search strategy for identifying randomized controlled
trials in CINAHL:
S1 MH Random Assignment or MH Single-blind Studies or MH Double-blind Studies or MH Triple-blind Studies or MH
Crossover design or MH Factorial Design
S2 TI (“multicentre study” or “multicenter study” or “multi-centre study” or “multi-center study”) or AB (“multicentre study”
or “multicenter study” or “multi-centre study” or “multi-center study”) or SU (“multicentre study” or “multicenter study” or “multi-
centre study” or “multi-center study”)
S3 TI random* or AB random*
S4 AB “latin square” or TI “latin square”
S5 TI (crossover or cross-over) or AB (crossover or cross-over) or SU (crossover or cross-over)
S6 MH Placebos
S7 AB (singl* or doubl* or trebl* or tripl*) or TI (singl* or doubl* or trebl* or tripl*)
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S8 TI blind* or AB mask* or AB blind* or TI mask*
S9 S7 and S8
S10 TI Placebo* or AB Placebo* or SU Placebo*
S11 MH Clinical Trials
S12 TI (Clinical AND Trial) or AB (Clinical AND Trial) or SU (Clinical AND Trial)
S13 S1 or S2 or S3 or S4 or S5 or S6 or S9 or S10 or S11 or S12
Appendix 6. CANCERLIT (PubMed Cancer Subset) search strategy
((neoplasm* OR leukemia OR leukaemia OR leukaemia OR lymphoma* OR plasmacytoma OR “histiocytosis malignant” OR retic-
uloendotheliosis OR “sarcoma mast cell” OR “Letterer Siwe disease” OR “immunoproliferative small intestine disease” OR “Hodgkin
disease” OR “histiocytosis malignant” OR “bone marrow transplant*” OR cancer* Or tumor* OR tumour* OR malignan* OR neu-
tropeni* OR carcino* OR adenocarcinoma* OR radioth* OR radiat* OR radiochemo* OR irradiat* OR chemotherap*) AND (stom-
atitis OR “Stevens Johnson syndrome” OR “candidiasis oral” OR mucositis OR (oral AND (candid* OR mucos* OR fung*)) OR
mycosis OR mycotic OR thrush))
The above subject search was run with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomized trials in
MEDLINE: sensitivity maximising version (September 2009 revision) as referenced in Chapter 6 and detailed in box 6.4.a of The Cochrane
Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]
#1 randomized controlled trial [pt]
#2 controlled clinical trial [pt]
#3 randomized [tiab]
#4 placebo [tiab]




#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
#10 animals [mh] NOT humans [mh]
#11 #9 NOT #10
Appendix 7. OpenSIGLE search strategy
SIGLE no longer supports complex searching, so a series of keyword searches was performed as below:
cancer AND mucositis AND oral
leukemia AND mucositis AND oral
leukaemia AND mucositis AND oral
carcinoma AND mucositis AND oral
lymphoma AND mucositis AND oral
tumour AND mucositis AND oral
tumor AND mucositis AND oral
cancer AND candidiasis AND oral
leukemia AND candidiasis AND oral
leukaemia AND candidiasis AND oral
carcinoma AND candidiasis AND oral
lymphoma AND candidiasis AND oral
tumour AND candidiasis AND oral
tumor AND candidiasis AND oral
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Appendix 8. LILACS via the Virtual Health Library search strategy
(www.bireme.org)
Mh NEOPLASMS OR Tw neoplasm$ OR Tw cancer$ OR Tw carcinoma$ OR Tw tumour$ OR Tw tumor$ OR Tw malignan$
OR Tw carcino$ OR Tw nuetropeni$ OR Tw adenocarcinoma$ OR Mh leukemia OR Tw leukaemia$ OR Tw leukemi$ OR Tw
lymphoma$ OR Tw “bone marrow transplantation” OR Tw “bone marrow transplant$” OR Tw radiotherapy OR Tw radioth$ OR
Tw radiat$ OR Tw irradiat$ OR Tw radiochemo$ OR Tw chemo$
AND
Mh stomatitis OR Tw stomatitis OR Mh Candidiasis-Oral OR Tw “oral candidiasis” OR (Tw candida$ AND (Tw mouth OR Tw
oral)) OR Tw mucositis OR ((Tw oral OR mouth) AND Tw fung$) OR (Tw oral AND Tw candidiasis$)
The above subject search was run with the Brazilian Cochrane Centre highly sensitive search strategy for identifying randomized
controlled trials in LILACS:
((Pt randomized controlled trial OR Pt controlled clinical trial ORMh randomized controlled trials ORMh random allocation ORMh
double-blind method ORMh single-blind method) ANDNOT (Ct animals AND NOT (Ct human and Ct animal)) OR (Pt clinical
trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$))
OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR
Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) ORMh placebos OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR
Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research design) AND NOT (Ct animals AND NOT (Ct human
and Ct animals)) OR (Ct comparative study OR Ex E05.337$ ORMh follow-up studies ORMh prospective studies OR Tw control$
OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animals AND NOT (Ct human and Ct animals)))
F E E D B A C K
Low level laser, 9 August 2010
Summary
“I ask you to file and publish the following comment:
There seems to be an imbalance in the way that low level laser therapy (LLLT) is handled in the risk of bias assessment and the review
conclusion. The two LLLT-studies receive the highest method scores of the review with 7/7 and 6/7 points, respectively, and no red
circles for high bias risk in the assessments. Still in the results section, the Kuhn (6/7) LLLT study is classified as having high risk of
bias. Although the scientific evidence may be classified as limited for LLLT in oral mucositis, I cannot see that the published conclusion
of weak and unreliable evidence is justified for studies receiving such extraordinarily high method scores. Another matter is that the
review only includes less than half of the published LLLT trials in cancer therapy-induced oral mucositis.”
Reply
The Kuhn 2009 study was correctly assessed as being at unclear risk of bias under the heading Effects of Interventions- Laser versus
sham treatment, but was not included in the group at unclear risk of bias, under the heading Risk of Bias. This error has been corrected.
We have amended the text in the Abstract, Results &Discussion sections concerning low level laser therapy, deleting the word unreliable
and describing the evidence as limited. The term ’unreliable’ has been added to the description of the evidence for patient controlled
analgesia as these trials are at either unclear or high risk of bias.
We believe that we have included all of the trials of low level laser therapy for the treatment of oral mucositis that meet the inclusion
criteria for this review. An update of a second systematic review of interventions for the prevention of oral mucositis is nearing completion
and is due to be published later this year. We would be grateful if Professor Bjordal could send us information about other trials that
he believes should be included in these review(s).
We would like to thank Professor Bjordal for taking the time to bring these matters to our attention.
Contributors
Professor Jan Bjordal, Centre for Evidence-based Practice, Bergen University College, Norway
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WH A T ’ S N E W
Last assessed as up-to-date: 31 May 2010.
Date Event Description
24 August 2010 Feedback has been incorporated Error concerning overall risk of bias categorisation for Kuhn 2009 corrected.
Wording changed in results and discussion sections concerning low level laser
treatment, in response to feedback received
H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 1, 2002
Date Event Description
6 July 2010 New search has been performed New searches up to 01 June 2010.
6 July 2010 New citation required and conclusions have changed 5 new included studies, 8 new excluded studies. Risk
of bias assessments completed on all included studies.
Added new outcome: proportion of patients with mild/
moderatemucositis. Review restructured to reflectmany
of comparisons have only one trial and to downgrade
this. 4 new authors
17 June 2008 Amended Converted to new review format.
16 February 2007 New citation required and conclusions have changed Substantive amendment. In this update we have added
1 included and 28 excluded studies
C O N T R I B U T I O N S O F A U T H O R S
Jan Clarkson (JC) and Helen Worthington (HW) wrote the protocol and review. HW co-ordinated the review and wrote the letters
to authors. HW, JC and Susan Furness independently and in duplicate assessed the eligibility of trials, extracted data and assessed the
risk of bias of the trials. HW conducted the statistical analysis. Tasneem Khalid provided advice on the interventions and Stefan Meyer
and Martin McCabe provided input on the cancer treatments and the assessment of mucositis, along with methodological input and
checking of data.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• The University of Manchester, UK.
• Scottish Executive Health Department, UK.
• University of Dundee, UK.
• NHS Education for Scotland, UK.
• Manchester Biomedical Research Centre, University of Manchester, UK.
• Cancer Research UK, UK.
• Teenage Cancer Trust, UK.
External sources
• NIDCR grant ref 1 DE01 6950-01, USA.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
New outcome added for 2010 update: proportion of patients with severe mucositis.
Two new outcomes added for 2005 update: time taken to heal mucositis; duration of pain control therapy.
N O T E S
Changes from protocol.
The title has changed.
The hypotheses have changed. The original first hypothesis has been expanded into two hypotheses one for eradication and one for
improvement of mucositis. The second original hypothesis has been changed from “there is no difference in the proportion of patients
with relief of pain” to “there is no difference in the mean pain scores”. This change was made as all studies reported pain as mean and
standard deviations of VAS scores.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Analgesics [therapeutic use]; Anti-Ulcer Agents [therapeutic use]; Laser Therapy, Low-Level [methods]; Mouth Diseases [etiology;
therapy]; Neoplasms [∗drug therapy; ∗radiotherapy]; Oral Ulcer [etiology; ∗therapy]; Pain [etiology]; Pain Management; Randomized
Controlled Trials as Topic; Stomatitis [etiology; ∗therapy]
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MeSH check words
Humans
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